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A B S T R A C T
Background
Mortality and morbidity from acute myocardial infarction (AMI) remain high. Intravenous magnesium started early after the onset of
AMI is thought to be a promising adjuvant treatment. Conflicting results from earlier trials and meta-analyses warrant a systematic
review of available evidence.
Objectives
To examine the effect of intravenous magnesium versus placebo on early mortality and morbidity.
Search strategy
We searched CENTRAL (The Cochrane Library Issue 3, 2006), MEDLINE (January 1966 to June 2006) and EMBASE (January
1980 to June 2006), and the Chinese Biomedical Disk (CBM disk) (January 1978 to June 2006). Some core Chinese medical journals
relevant to the cardiovascular field were hand searched from their starting date to the first-half year of 2006.
Selection criteria
All randomized controlled trials that compared intravenous magnesium with placebo in the presence or absence of fibrinolytic therapy
in addition to routine treatment were eligible if they reported mortality and morbidity within 35 days of AMI onset.
Data collection and analysis
Two reviewers independently assessed the trial quality and extracted data using a standard form. Odds ratio (OR) were used to pool
the effect if appropriate. Where heterogeneity of effects was found, clinical and methodological sources of this were explored.
Main results
For early mortality where there was evidence of heterogeneity, a fixed-effect meta-analysis showed no difference between magensium
and placebo groups (OR 0.99, 95%CI 0.94 to 1.04), while a random-effects meta-analysis showed a significant reduction comparing
magnesium with placebo (OR 0.66, 95% CI 0.53 to 0.82). Stratification by timing of treatment (< 6 hrs, 6+ hrs) reduced heterogeneity,
and in both fixed-effect and random-effects models no significant effect of magnesium was found. In stratified analyses, early mortality
was reduced for patients not treated with thrombolysis (OR=0.73, 95% CI 0.56 to 0.94 by random-effects model) and for those treated
with less than 75 mmol of magnesium (OR=0.59, 95% CI 0.49 to 0.70) in the magnesium compared with placebo groups.
Meta-analysis for the secondary outcomes where there was no evidence of heterogeneity showed reductions in the odds of ventricular
fibrillation (OR=0.88, 95% CI 0.81 to 0.96), but increases in the odds of profound hypotension (OR=1.13, 95% CI 1.09 to 1.19)
and bradycardia (OR=1.49, 95% CI 1.26 to 1.77) comparing magnesium with placebo. No difference was observed for heart block
(OR=1.05, 95% CI 0.97-1.14). For those outcomes where there was evidence of heterogeneity, meta-analysis with both fixed-effect
and random-effects models showed that magnesium could decrease ventricular tachycardia (OR=0.45, 95% CI 0.31 to 0.66 by fixed-
effect model; OR=0.40, 95% CI 0.19 to 0.84 by random-effects model) and severe arrhythmia needing treatment or Lown 2-5 (OR=
0.72, 95% CI 0.60 to 0.85 by fixed-effect model; OR=0.51, 95% CI 0.33 to 0.79 by random-effects model) compared with placebo.
There was no difference on the effect of cardiogenic shock between the two groups.
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Authors’ conclusions
Owing to the likelihood of publication bias and marked heterogeneity of treatment effects, it is essential that the findings are interpreted
cautiously. From the evidence reviewed here, we consider that: (1) it is unlikely that magnesium is beneficial in reducing mortality
both in patients treated early and in patients treated late, and in patients already receiving thrombolytic therapy; (2) it is unlikely
that magnesium will reduce mortality when used at high dose (>=75 mmol); (3) magnesium treatment may reduce the incidence of
ventricular fibrillation, ventricular tachycardia, severe arrhythmia needing treatment or Lown 2-5, but it may increase the incidence
of profound hypotension, bradycardia and flushing; and (4) the areas of uncertainty regarding the effect of magnesium on mortality
remain the effect of low dose treatment (< 75 mmol) and in patients not treated with thrombolysis.
P L A I N L A N G U A G E S U M M A R Y
In some countries, intravenous (IV) magnesium is administered to heart attack patients in order to limit damage to the heart muscle,
prevent serious arrhythmias and reduce the risk of death. Several small trials appeared to support the practice. But the authors of this
review found that other trials went unpublished once they produced unfavorable results. A controversy erupted in 1995, when a large
well-designed trial with 58,050 participants did not demonstrate any beneficial effect to IV magnesium, contradicting earlier meta-
analyses of the smaller trials. This review includes 26 clinical trials that had randomly assigned heart attack patients to receive either IV
magnesium or an inactive substance (placebo). Their results were mixed: IV magnesium reduced the incidence of serious arrhythmias,
but this treatment also increased the incidence of profound hypotension, bradycardia and flushing. However, any apparent beneficial
effects of magnesium may simply reflect various biases in these trials. Additionally, there was a lack of uniformity in these trials in terms
of dosage and the timing of the IV magnesium regimen, which in some trials also included anti-clotting drugs. The evidence produced
by this review does not support continued use of IV magnesium. Other effective treatments (aspirin, beta-blockers) should be used to
treat heart attack.
B A C K G R O U N D
Cardiovascular disease remains the leading cause of death in de-
veloped countries, and acute myocardial infarction accounts for a
large proportion of these deaths. The major determinant of mor-
tality and morbidity of acute myocardial infarction is infarct size.
Many early deaths are due to ventricular fibrillation but in patients
who survive the first few hours, the outcome is largely determined
by the extent of myocardial damage.
Magnesium probably functions as an inorganic calcium channel
blocker and there are several plausible mechanisms for a benefi-
cial effect in acute myocardial infarction (Woods 1991). Research
on animals and humans has shown that magnesium is a periph-
eral (Mroczek 1977) and coronary vasodilator (Vigorito 1991). It
can increase the threshold for depolarization of cardiac myocytes,
thereby reducing the likelihoodof cardiac arrhythmia caused by in-
jury currents near ischaemic or infarcted tissue (Haverkamp 1988;
Tzivoni 1990). Magnesium decreases reperfusion injury by pre-
venting or lessening mitochondrial calcium overload in ischaemic
myocardial cells during the first few minutes of reperfusion (Fer-
rari 1986) (namely, the restoration of blood flow to an organ or
tissue) and preserving intracellular ATP and creatine phosphate
reserves (Borchgrevink 1989), and inhibits platelet function, per-
haps indirectly by release of prostacyclin (Watson 1986). Thus,
magnesium infusion started early after the onset of myocardial is-
chaemia might limit infarct size, prevent serious arrhythmias, and
reduce mortality.
However, the clinical role of magnesium is still uncertain. The role
of intravenous magnesium therapy in patients with acute myocar-
dial infarction is controversial. The results from previous clinical
trials are not in agreement. Several trials and pooled analyses of
their results demonstrated a mortality rate reduction with mag-
nesium treatment (Egger 1994; Horner 1992; Teo 1991; Yusuf
1993), but were later contradicted by one large trial, ISIS-4 (ISIS-4
1995).
Proposed explanations for the lack of consistency between the
mega-trial ISIS-4 and the meta-analyses of the small trials, includ-
ingLIMIT-2 (Woods 1992), are related to the timingof treatment,
the dose of magnesium used, the duration of treatment, concomi-
tant thrombolysis and methodological problems (i.e. publication
bias, statistical models used).
• Timing of intravenous magnesium regimen and thrombolytic
treatment
The magnesium in ISIS-4 was, on average, given later than in
LIMIT-2, and was started after (rather than before or within) the
initial ’lytic’ phase of fibrinolytic therapy (ISIS-4 1995; Woods
1992).
• The dose of magnesium given in the first 24 hours
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Examination of the dose effect in a meta-analysis of eight stud-
ies (Horner 1992), LIMIT-2 (Woods 1992) and ISIS-4 (ISIS-4
1995), showed that the dose of intravenous magnesium given in
the first 24 hours was related to the relative risk (RR) of death in
the magnesium group versus placebo (Galloe 1994). A curvilinear
correlation indicated a significant correlation between dose and
effect. Mortality decreases following administration of between
0 mmol and 55 mmol magnesium. The optimum reduction in
mortality (RR 0.36) was obtained at a dose of 55 mmol magne-
sium. Mortality increased between 55 mmol and 75 mmol, but
the relative risk of death was still below 1 (the benefit was larger
than any harm). Over 75 mmol magnesium, any beneficial treat-
ment effect appeared to be lost (RR of death was more than 1).
In ISIS-4 the initial 8 mmol bolus was given over approximately
15 minutes with a 24-hour infusion dose of 72 mmol compared
with initial 8 mmol bolus given in approximately 5 minutes with
a 24-hour infusion dose of 65 mmol in LIMIT-2. Therefore it has
been (Galloe 1994) proposed that the absence of effect in ISIS-4
could be related to the dose used in the first 24 hours which might
resulted in a higher prevalence of hypotension, II-III degree atri-
oventricular block, heart failure and cardiac shock.
• The duration of magnesium regimen
For most of the small trials, the intravenous magnesium infusion
continued for 48 hours (rather than 24 hours in LIMIT-2 and
ISIS-4) before showing any benefit (especially an antiarrhythmic
effect), therefore the optimal duration of magnesium treatment
remains to be clarified.
• Concomitant treatment
The proportion of patients who did not receive thrombolysis was
65% in LIMIT-2, more than twice the proportion not given
thrombolysis in ISIS-4 (30%), therefore the use of thrombolysis
might overlap or obscure any potential beneficial actions of mag-
nesium when both drugs are used in combination. Besides, other
drugs such as aspirin,β-blockers, nitrate, heparin and angiotensin-
converting-enzyme inhibitors, etc could also influence the effect
of magnesium.
• Bias in conducting meta-analysis
Egger et al (Egger 1995; Egger 1997) studied the value of funnel
plots (plots of effect estimates against sample size) in detecting bias
in meta-analysis and found that the funnel plots for magnesium
and acute myocardial infarction were not symmetrical which in-
dicated the possible presence of publication bias.
• Statistical models used in previous meta-analysis
Use of specific statistical modelsmay affect outcome.When ISIS-4
is added to the earlier RCTs, the fixed effect model that assumes
homogeneity among the trials indicates no beneficial effect ofmag-
nesium (OR = 1.02, 95%CI 0.96 to 1.08, P = 0.48), whereas the
random effects model that takes into account the heterogeneity
among these trials suggests that magnesium may reduce mortality
(OR = 0.59, 95%CI 0.39 to 0.90, P = 0.014) (Antman 1995a;
Antman 1996).
Considering the conflicting results of previous meta-analyses and
later large trials, and the possibility of bias in these meta-analyses,
we propose that further clarification of the effect of magnesium
on the mortality and morbidity of acute myocardial infarction is
warranted.
O B J E C T I V E S
In patients suffering acute myocardial infarction:
• To examine the effect of intravenous magnesium versus control
on early mortality (primary objective), stratified by time since
onset of symptoms (< 6 hours, 6+ hours), use of thrombolysis
(used, not used), dose of magnesium used (< 75 mmol, 75+
mmol);
• To examine the effect of intravenous magnesium versus control
on early morbidity (secondary objective), including ventricular
fibrillation and tachycardia, atrioventricular block, bradycardia,
heart failure, cardiogenic shock, hypotension, severe arrhythmia
needing treatment or Lown 2-5, and flushing.
Early outcomes are defined as mortality and morbidity occurring
in hospital during the acute admission phase or within 35 days of
onset of MI. Lown 2-5 is defined as frequent or complex ventricu-
lar arrhythmia based on 24-hour electrocardiogram (ECG) record-
ings and analyses of ventricular arrhythmias (Hedblad 1997).
Since the definition of clinical events such as heart failure, cardio-
genic shock, bradycardia and hypotension varied in different trials,
the presence of these clinical events was based on the investigators’
judgement.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
All randomized controlled trials that compared intravenous mag-
nesium with placebo in the presence or absence of thrombolytic
therapy in addition to routine treatment were eligible if they re-
ported mortality and clinical events within 35 days of acute my-
ocardial infarction onset, published in any language.
Types of participants
All patients with first-time acute myocardial infarction or sus-
pected myocardial infarctionin the preceding 24 hours diagnosed
by clinical symptoms, enzymes andECG, regardless of age, gender,
infarct size and location, and without contraindication to magne-
sium.
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Types of intervention
• Experimental treatment: intravenous magnesium plus routine
treatment in the presence or absence of thrombolytic therapy
• Control treatment: routine treatment in the presence or absence
of thrombolytic therapy
Types of outcome measures
The following outcomes within the first 5-week were considered:
• Primary outcome: within 5-week total mortality
• Secondary outcomes: ventricular fibrillation and tachycardia,
atrioventricular block, bradycardia, heart failure, cardiogenic
shock, hypotension, severe arrhythmia needing treatment or
Lown 2-5, flushing
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Heart Group methods used in reviews.
We searched the Cochrane Centreal Register of Controlled
Trials (CENTRAL) on The Cochrane Library (Issue 3, 2006),
MEDLINE (January 1966 to June 2006), EMBASE (January
1980 to June 2006), and the Chinese Biomedical Disk (CBM
disk) (January 1978 to June 2006). No language restrictions were
applied.
Since CENTRAL does not cover most Chinese medical journals
and the index of randomized controlled trials in the Chinese
Biomedical Disk is not complete, therefore some core Chinese
medical journals relevant to the cardiovascular area were hand
searched from their starting date to the first-half year of 2006,
including Chinese Journal of Cardiology, Chinese Circulation
Journal, Chinese Journal of Interventional Cardiology, Chinese
Journal of Hypertension, and Journal of Clinical Cardiology.
The bibliographies of the randomised trials were reviewed and
the authors, and known experts in the field, were contacted to
identify additional published or unpublished data.
The electronic search of CENTRAL was performed using the
following specific terms, similar terms were used to search
MEDLINE, EMBASE and CBM:
#01MYOCARDIAL-ISCHEMIA*:ME
#02CORONARY-ARTERY-BYPASS*:ME
#03(ISCHEMI* near HEART)
#04(ISCHAEMI* near HEART)
#05(CORONARY near DISEASE*)
#06(CORONARY near BYPASS)
#07(CORONARY near THROMBO*)
#08(CORONARY near ANGIOPLAST*)
#09(MYOCARD* near ISCHEMI*)
#10(MYOCARD* near ISCHAEMI*)
#11(MYOCARD* near INFARCT*)
#12(HEART near INFARCT*)
#13ANGINA
#14(((((((#1 or #2) or #3) or #4) or #5) or #6) or #7) or #8)
#15((((#9 or #10) or #11) or #12) or #13)
#16(#14 or #15)
#17MAGNESIUM*:ME
#18MAGNESIUM-COMPOUNDS*:ME
#19MAGNESI*
#20((#17 or #18) or #19)
#21(#16 and #20)
M E T H O D S O F T H E R E V I E W
Study selection
Two members of the review team independently reviewed the
abstracts of randomized controlled trials to identify the trials
that met the eligibility criteria. English and Chinese trials were
reviewed. However, all English abstracts of non-English, non-
Chinese language publications were also reviewed to collect
available data of interests.
Trials were only rejected on initial screen if the reviewer could
determine from the title and abstract that the trial was not a report
of a randomized controlled trial or the trial did not address the
effect of intravenous magnesium on the mortality and morbidity
of acute myocardial infarction.
When a title/abstract could not be rejected with certainty, the full
text of the articlewas obtained for further evaluation. An inclusion/
exclusion form was used to assist the selection of the trials.
Methodological quality assessment
The methodological quality was assessed by taking into account
the method of randomization, allocation concealment, blinding
of participants and investigators, and completeness of follow-up.
The allocation concealment was graded as A: adequate, B: unclear,
C: inadequate and D: unknown.
Data extraction
A data extraction form was used to extract information from
the eligible trials, regarding participants, interventions, outcomes,
study quality and pre-tested using a random sample of studies.
The key information of each section of the data extraction form
was as following:
1. Participants: inclusion and exclusion criteria, baseline
characteristics as age, gender and comorbid conditions, etc.
2. Intervention: dose, length of intravenous magnesium, timing
of magnesium with thrombolytic therapy, concomitant treatment
and treatment of control group, etc.
3. Outcomes: number of outcome
events including mortality and morbidity (ventricular fibrillation
and tachycardia, atrioventricular block, bradycardia, heart failure,
cardiogenic shock, hypotension, flushing).
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Two reviewers (Jing Li, and either Qing Zhang or Mingming
Zhang) independently conducted the selection of studies,
assessment of methodological quality of included studies and data
extraction. Disagreement was resolved by discussion and, when
necessary, in consultation with a third person.Whenever there was
uncertainty, authors were contacted to clarify the details.
Data analysis
ReviewManager 4.2 (RevMan) software was used for the statistical
analysis. The odds ratio (OR) was used as the effect measure.
Heterogeneity was assessed and a fixed-effect model (assumes
that the true effect of treatment is the same value in every
study, namely fixed across studies) and/or a random-effects model
(assumes that the effects being estimated in the different studies
are not identical, but follow some distribution) was used, as
appropriate as determined by heterogeneity, to summarize the
evidence. Estimates of the relative rates of the outcomes were
pooled using standard methods for combining odds ratios for
early mortality stratified by time since onset of symptoms (< 6
hours, 6+ hours), use of thrombolysis (used, not used), dose of
magnesium used (< 75 mmol, 75+ mmol) and clinical events
of intravenous magnesium versus control . Ninety-five percent
confidence interval was used for all effect size estimates for both
individual trials and pooled estimates.
Heterogeneity was assessed using the the chi-squared test with
significance set at P < 0.10. Whenever there was heterogeneity and
it was considered feasible to pool the data, both fixed effect model
and random effects model were used.
Sensitivity analysis for the primary outcome was performed based
on the adequate of concealment of allocation. Publication bias and
other biases were examined using a funnel plot.
D E S C R I P T I O N O F S T U D I E S
See Table entitled “Characteristics of included studies”
Included studies
Forty-eight potentially relevant studies were identified after ex-
tensive searching and selection, of these, 26 RCTs with a total of
73363 participants were included in the review (Abraham 1987;
Bhargava 1995; Ceremuzynski 1989; Chen 1991; Feldstedt 1991;
Gyamlani 2000; Ising 1990; ISIS-4 1995; MAGIC 2000; Mor-
ton 1984; Nakashima 2004; Nameki 2004; Parikka 1999; Raghu
1999; Rasmussen 1986; Santoro 2000; Shechter 1990; Shechter
1991; Shechter 1995; Singh 1990; Smith 1986; Thogersen 1995;
Urek 1996; Woods 1992; Wu 1992; Zhu 2002).
Participants
The 26 trials varied in sample size (ranging from 40 to 58,050
participants), characteristics of patients (eight trials with suspected
acutemyocardial infarction patients (Feldstedt 1991; ISIS-4 1995;
Rasmussen 1986; Shechter 1995; Singh 1990; Smith 1986;
Thogersen 1995; Woods 1992) and the other 18 with proven
acute myocardial infarction patients). Of these, 22 trials (72,476
participants) contributed to the information on mortality, 11 tri-
als (62,392 participants) on ventricular fibrillation, 9 trials (1187
participants) on ventricular tachycardia, 9 trials (67,338 partici-
pants) on II-III degree heart block, 14 trials (68,140 participants)
on heart failure, 5 trials (60,668 participants) on profound hy-
potension, 12 trials (62,334 participants) on cardiogenic shock,
10 trials (7353 participants) on severe arrhythmia needing treat-
ment, 4 trials (60,574 participants) on bradycardia, and 5 trials
(58,744 participants) on flushing.
Interventions
The 26 trials varied in dose of magnesium within the first 24 hours
(sulphate, chloride or aspartate) ranging from8mmol to 80mmol.
Duration of treatment ranged from 5 hours to 14 days.
Outcomes
The 26 trials provided different outcomes and the follow-up pe-
riod varied from 24 hours to 5 weeks. The definition andmeasure-
ment of outcomes were different in different trials. Adverse effects
of bradycardia and flushing were reported in four trials (Bhargava
1995; ISIS-4 1995; Rasmussen 1986; Woods 1992) and five tri-
als (Abraham 1987; Gyamlani 2000; ISIS-4 1995; Raghu 1999;
Santoro 2000) respectively.
Excluded studies
Five papers were additional publications to studies already in-
cluded. Twelve studies were excluded for the following reasons: (1)
comparedmagnesiumwith other drugs such as propranolol (Abra-
ham 1994; Balkin 1994); (2) only abstracts, without available data
(Petri 1985; Smith 1985; Su 1997; Xu 1990); (3) long-term effect
of magnesium in acute myocardial infarction (Rasmussen 1988;
Shechter 2003; Woods 1994); (4) pilot study of ISIS-4 (Flather
1994); (5) not a randomized controlled trial (Leone 1991; Sun
1990).
Studies awaiting assessment
Five trials published in language other than English or Chinese
(Pereira 1990; Rekosz 1996; Spisak 1994; Yavelov 1995a; Yavelov
1995b). Translation is needed to assess eligibility and collect the
available data.
M E T H O D O L O G I C A L Q U A L I T Y
Thirteen trials provided the methods to generate randomization
sequence (Abraham 1987; Bhargava 1995; Feldstedt 1991; Gyam-
lani 2000; ISIS-4 1995; MAGIC 2000; Morton 1984; Raghu
1999; Santoro 2000; Shechter 1995; Thogersen 1995; Woods
1992; Zhu 2002). Sixteen trials stated use of double blinding
(Abraham 1987; Feldstedt 1991; Gyamlani 2000; MAGIC 2000;
Morton 1984; Parikka 1999; Raghu 1999; Rasmussen 1986;
Shechter 1990; Shechter 1991; Shechter 1995; Singh 1990; Smith
1986; Thogersen 1995; Urek 1996; Woods 1992); two stated use
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of single blinding (Chen 1991; Nakashima 2004). Nine trials used
adequate allocation concealment (Gyamlani 2000; ISIS-4 1995;
MAGIC 2000; Raghu 1999; Santoro 2000; Shechter 1995; Singh
1990; Smith 1986; Woods 1992). Seven trials mentioned inten-
tion-to-treat analysis (Feldstedt 1991; ISIS-41995;MAGIC2000;
Santoro 2000; Singh 1990; Thogersen 1995; Woods 1992).
R E S U L T S
When there was no heterogeneity for the outcome, a fixed effect
model was used to pool the data. Whenever heterogeneity was
observed for the primary outcome (even after stratification) and
secondary outcomes, both fixed and random effects models were
used to pool the data.
Considering sources of clinical heterogeneity between the trials, it
was clear that the different selection criteria of participants (sus-
pected or confirmed acute myocardial infarction), characteristics
of participants especially the length of time between the onset of
symptoms and admission, dose of magnesium, the duration of in-
tervention and follow up, and criteria for outcome measurement
might explain heterogeneity among trials. To attempt to explore
some of these sources of heterogeneity, we examined the effect of
intravenous magnesium versus control on early mortality strati-
fied by time since onset of symptoms (< 6 hours, 6+ hours), use
of thrombolysis (used, not used), dose of magnesium used (< 75
mmol, 75+ mmol).
Effect of intravenous magnesium versus control on early mor-
tality
There was significant heterogeneity among trials (X2= 57.77, P <
0.0001) for the primary outcome of early mortality. Fixed-effect
meta-analysis showed no difference in early mortality between
the two groups (OR 0.99, 95%CI 0.94 to 1.04), while random-
effects meta-analysis showed a significant reduction comparing
magnesium with placebo (OR 0.66, 95% CI 0.53 to 0.82).
Stratified by time since onset of symptoms (< 6 hours, 6+ hours)
Eight trials (Abraham 1987; Gyamlani 2000; ISIS-4 1995;
MAGIC 2000; Morton 1984; Raghu 1999; Santoro 2000; Woods
1992) provided information on early mortality, 16,320 partic-
ipants on magnesium (1503 died) and 16,286 participants in
placebo (1502 died) groups were admitted to hospitals less than
6 hours after the onset of symptoms. Heterogeneity was observed
among trials (X2=16.41, P = 0.02) and no difference was observed
between the magnesium and placebo groups via both fixed effect
model (OR = 1.00, 95% CI 0.93 to 1.08) and random effects
model (OR = 0.88, 95% CI 0.72 to 1.08).
Two trials (ISIS-4 1995; Singh 1990) provided information on
early mortality, 17,414 participants on magnesium (1294 died)
and 17,471 participants on placebo (1234 died) groups were ad-
mitted to the hospital after 6 hours of onset of symptoms. There
was no heterogeneity and no difference was observed between the
two groups (OR = 1.06, 95% CI 0.97 to 1.15).
Stratified by use of thrombolysis (used, not used)
Four trials (ISIS-4 1995; MAGIC 2000; Raghu 1999; Zhu 2002)
reported the use of thrombolysis in 21,873 (1618 died) partici-
pants on magnesium and 21,573 (1502 died) on placebo. There
was heterogeneity among trials (X2=11.36, P = 0.01). Meta-analy-
sis with both fixed-effectmodel (OR = 1.07, 95%CI 0.99 to 1.15)
and random effects model (OR = 0.91, 95% CI 0.69 to 1.20)
showed that there was no difference on early mortality between
the two groups.
Twelve trials (Abraham 1987; Feldstedt 1991; ISIS-4 1995;
MAGIC 2000; Morton 1984; Rasmussen 1986; Shechter 1990;
Shechter 1991; Shechter 1995; Singh 1990; Smith 1986; Zhu
2002) with 12,230 (1176 died) participants in magnesium and
12,362 (1269 died) in placebo groups did not use thrombolysis.
There was heterogeneity among trials (X2= 25.69, P = 0.007).
Meta-analysis with a fixed-effect model showed no difference on
early mortality in the magnesium group compared with placebo
(OR=0.93, 95% CI 0.86-1.01), while a random-effects model
showed a decrease in early mortality (OR = 0.73, 95% CI 0.56 to
0.94).
Stratified by dose of magnesium used (< 75 mmol, 75+ mmol)
Seventeen trials (Abraham 1987; Bhargava 1995; Ceremuzynski
1989; Gyamlani 2000; Nakashima 2004; Rasmussen 1986; San-
toro 2000; Shechter 1990; Shechter 1991; Shechter 1995; Singh
1990; Smith 1986; Thogersen 1995; Urek 1996; Woods 1992;
Wu 1992; Zhu 2002) with 33,850 (228 died) participants in mag-
nesium and 3639 (355 died) in placebo groups infused magne-
sium less than 75 mmol within the first 24 hours. There was no
heterogeneity among trials (X2= 16.97, P = 0.39) and meta-anal-
ysis showed a decrease in early mortality compared with placebo
(OR = 0.59, 95% CI 0.49 to 0.70).
Five trials (Feldstedt 1991; ISIS-4 1995; MAGIC 2000; Morton
1984; Raghu 1999) with 32,483 (2708 died) participants magne-
sium and 32,504 (2603 died) in placebo groups infused magen-
sium 75 mmol or more within the first 24 hours. There was no
heterogeneity (X2= 6.72, P = 0.15) among trials and meta-analysis
showed that there was no difference on early mortality between
the two groups (OR = 1.04, 95% CI 0.99 to 1.11).
Effect of intravenous magnesium versus control on early mor-
bidity
Ventricular fibrillation
Eleven trials (Abraham 1987; Bhargava 1995; Ceremuzynski
1989; Chen 1991; Feldstedt 1991; Gyamlani 2000; ISIS-4 1995;
Morton 1984; Nakashima 2004; Wu 1992; Zhu 2002) provided
information on ventricular fibrillation, 31,301 (1040 with ven-
tricular fibrillation) participants in magnesium and 31,091 (1168
with ventricular fibrillation) in placebo groups. There was no het-
erogeneity among trials (X2= 15.00, P = 0.13) and meta-analy-
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sis showed that magnesium could decrease ventricular fibrillation
compared with placebo (OR = 0.88, 95% CI 0.81 to 0.96).
Ventricular tachycardia
Nine trials (Abraham 1987; Bhargava 1995; Ceremuzynski 1989;
Chen 1991; Feldstedt 1991; Gyamlani 2000; Rasmussen 1986;
Santoro 2000; Wu 1992) provided information on ventricular
tachycardia, 601 (57 with ventricular tachycardia) participants in
magnesium and 586 (101 with ventricular tachycardia) in placebo
groups. There was heterogeneity among trials (X2= 23.94, P =
0.002). Meta-analysis with both a fixed-effect model (OR = 0.45,
95% CI 0.31 to 0.66) and random-effects model (OR = 0.40,
95% CI 0.19 to 0.84) showed that magnesium could decrease
ventricular tachycardia compared with placebo.
II-III heart block
Nine trials (Feldstedt 1991; ISIS-4 1995; MAGIC 2000; Parikka
1999; Shechter 1990; Shechter 1991; Shechter 1995; Urek 1996;
Woods 1992) provided information on II-III heart block, 33,662
(1231 with II-III heart block) participants in magnesium and
33,676 (1177 with II-III heart block) in placebo groups. There
was no heterogeneity among trials (X2= 8.89, P = 0.35) and meta-
analysis showed that no difference of effect on II-III heart block
between magnesium and placebo groups (OR = 1.05, 95% CI
0.97 to 1.14)
Heart failure
Fourteen trials (Feldstedt 1991; Gyamlani 2000; ISIS-4 1995;
MAGIC 2000; Morton 1984; Nakashima 2004; Parikka 1999;
Rasmussen 1986; Santoro 2000; Shechter 1990; Shechter 1991;
Shechter 1995; Woods 1992; Wu 1992 ) provided information on
heart failure, 34,066 (5920 with heart failure) participants inmag-
nesium and 34,074 (5602 with heart failure) in placebo groups.
There was heterogeneity among trials (X2=24.56, P=0.03). Meta-
analysis with a fixed-effect model showed that magnesium could
increase heart failure compared with placebo (OR=1.07, 95% CI
1.03 to 1.11), while a random-effects model showed that there is
no difference of effect (OR=0.95, 95% CI 0.81 to 1.10).
Considering the main sources of heterogeneity, we stratified heart
failure by time since onset of symptoms (< 6 hours, 6+ hours),
use of thrombolysis (used, not used), dose of magnesium used (<
75 mmol, 75+ mmol). Data were available for patients admitted
within 6 hours, not given thrombolysis and use of both low and
high dose magnesium. Homogenous effects were achieved except
for heart failure admitted within 6 hours. (1) Five trials (Gyamlani
2000; MAGIC 2000; Morton 1984; Santoro 2000; Woods 1992)
provided information on heart failure, 4437 (762 with heart fail-
ure) participants in magnesium and 4418 (769 with heart failure)
in placebo groups admitted patients within 6 hours. Heterogene-
ity was observed among trials (X2= 16.23, P = 0.003). Meta-anal-
ysis by both fixed-effect (OR = 0.92, 95% CI 0.63 to 1.36) and
random-effects models (OR = 0.98, 95%CI 0.88 to 1.10) showed
that there was no difference in heart failure between magnesium
and placebo groups. (2) Six trials (Feldstedt 1991; Morton 1984;
Rasmussen 1986; Shechter 1990; Shechter 1991; Shechter 1995)
which did not use thrombolysis provided information on heart
failure, 413 (59 with heart failure) participants in magnesium and
434 (56 with heart failure) in placebo groups. There was no het-
erogeneity among trials and no difference on effect of heart failure
between magnesium and placebo groups (OR = 1.11, 95% CI
0.74 to 1.68). (3) Ten trials (Gyamlani 2000; Nakashima 2004;
Parikka 1999; Rasmussen 1986; Santoro 2000; Shechter 1990;
Shechter 1991; Shechter 1995; Woods 1992; Wu 1992) that in-
fused less than 75 mmol magnesium within the first 24 hours pro-
vided information on heart failure, 1752 (233 with heart failure)
participants in magnesium and 1751 (300 with heart failure) in
placebo groups. There was no heterogeneity among trials. Meta-
analysis showed that magnesium could decrease heart failure com-
pared with placebo (OR = 0.73, 95% CI 0.60 to 0.88). Four trials
(Feldstedt 1991; ISIS-4 1995; MAGIC 2000; Morton 1984) that
infused 75 mmol or more magnesium within the first 24 hours
provided information on heart failure, 32,314 (5687 with heart
failure) participants in magnesium and 32,323 (5302 with heart
failure) in placebo groups. There was no heterogeneity among tri-
als andmeta-analysis showed thatmagnesium could increase heart
failure compared with placebo groups (OR = 1.09, 95% CI 1.04
to 1.13).
Profound hypotension
Five trials (Abraham 1987; ISIS-4 1995; Morton 1984; Singh
1990; Woods 1992) provided information on profound hypoten-
sion, 30,324 (4854 with profound hypotension) participants in
magnesium and 30,344 (4367 with profound hypotension) in
placebo groups. There was no heterogeneity among trials and
meta-analysis showed that magnesium could increase profound
hypotension compared with placebo groups (OR = 1.13, 95% CI
1.09 to 1.19).
Cardiogenic shock
Twelve trials (Abraham 1987; Bhargava 1995; Ceremuzynski
1989;Gyamlani 2000; ISIS-4 1995;Nakashima 2004; Rasmussen
1986; Shechter 1990; Shechter 1991; Shechter 1995; Singh 1990;
Zhu 2002) provided information on cardiogenic shock, 31,243
(1360 with cardiogenic shock) participants in magnesium and
31,091 (1268 with cardiogenic shock) in placebo groups. There
was heterogeneity among trials (X2= 21.80, P = 0.03). Meta-anal-
ysis with both fixed-effect (OR = 1.07, 95% CI 0.99 to 1.16) and
random-effects models (OR = 0.65, 95%CI 0.41 to 1.02) showed
that there was no difference on the effect of cardiogenic shock
between the two groups.
Severe arrhythmia needing treatment or Lown 2-5
Ten trials (Chen 1991; MAGIC 2000; Rasmussen 1986; Shechter
1990; Shechter 1991; Shechter 1995; Singh 1990; Smith 1986;
Urek 1996; Wu 1992) provided information on severe arrhyth-
mia needing treatment or Lown 2-5, 3682 (258 with severe ar-
rhythmia needing treatment or Lown 2-5) participants in mag-
nesium and 3671 (341 with severe arrhythmia needing treatment
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or Lown 2-5) in placebo groups. There was heterogeneity among
trials (X2= 23.94, P = 0.002). Meta-analysis with both fixed-effect
(OR = 0.72, 95% CI 0.60 to 0.85) and random-effects models
(OR = 0.51, 95% CI 0.33 to 0.79) showed that magnesium could
decrease severe arrhythmia needing treatment or Lown 2-5 com-
pared with placebo.
Effect of intravenous magnesium versus control on adverse
effects
Bradycardia
Four trials (Bhargava 1995; ISIS-4 1995; Rasmussen 1986;Woods
1992) with 30,266 (340 with bradycardia) participants in mag-
nesium and 30,308 (233 with bradycardia) in placebo groups re-
ported information on bradycardia. There was no heterogenity
and meta-analysis showed that magnesium infusion caused more
bradycardia compared with placebo treatment (OR = 1.49, 95%
CI 1.26 to 1.77).
Flushing
Five trials (Abraham 1987; Gyamlani 2000; ISIS-4 1995; Raghu
1999; Santoro 2000) with 29,353 (269 with flushing) participants
in magnesium and 29,391 (12 with flushing) in placebo groups
reported information on flushing. There was heterogeneity among
trials (x2= 23.81, P < 0.0001). Meta-analysis with both fixed-effect
(OR = 20.78, 95%CI 12.90 to 33.46) and random-effects models
showed that magnesium infusion caused more flushing compared
with placebo treatment (OR = 42.00, 95% CI 3.82 to 461.35).
A visual inspection of the funnel plot for early mortality showed
evidence of absence of small negative trials (Figure 01).
D I S C U S S I O N
Although the benefit and harm of magnesium have been debated
over two decades and 73,363 patients have been studied in a series
of 26 randomized controlled trials of magnesium over the past 26
years, there is still uncertainty about its effects. Focusing on the
effect on early mortality, the most important outcome and least
likely to be affected by difficulties with blinding or diagnostic cri-
teria, it is clear that the findings from the smaller trials are not
consistent with those of the very large ISIS-4 trial (which provided
71.65% of the overall weight of the meta-analysis), with substan-
tial heterogeneity apparent (I2 = 63.6%). In these circumstances,
a fixed-effect model gives a null effect (OR = 0.99, 95%CI 0.94 to
1.04), and a random-effects model, which gives much less weight
to ISIS-4, appears to demonstrate a benefit of magnesium (OR =
0.66, 95%CI 0.53 to 0.82). It has been argued that neither analysis
is appropriate and that a Bayesian perspective can help reconcile
the discordant ISIS-4 findings from the other trials. In this work, a
sceptical prior together with a random-effects model resulted in a
consistent, non-significant, effect onmortality whether ISIS-4 was
included or excluded from consideration (Higgins 2002). How-
ever, it is essential to consider the possibility of publication bias as
an explanation for the difference between ISIS-4 (and MAGIC,
also large and null) and the other smaller trials. Egger’s original
exploration demonstrated evidence of an absence of small negative
trials (Egger 1997) and this more detailed and updated search has
failed to find any further small negative trials.
A question to be considered is whether ISIS-4 produced the
’wrong’ answer by treating patients too late, using toohigh a dose of
magnesium, or treating too many people on concomitant throm-
bolytic therapy. To examine this question, we examined the results
stratified by these trial characteristics to determine whether het-
erogeneity within strata was reduced and whether the treatment
effects differed between strata. In view of the hazards of generating
spurious findings from sub-group analyses, we have limited our
interpretation to the primary outcome of interest, early mortality.
• Time is critical in management of acute myocardial infarction.
If thrombolytic treatment is not given, spontaneous reperfu-
sion occurs in at least a third of patients during the first 12 to
24 hours after acute myocardial infarction (Woods 1995). The
benefits from supplemental magnesium administration may be
lost when there is a delay ofmore than 15 to 45minutes after the
onset of reperfusion (Antman 1995b). Although most included
trials reported the time of acute myocardial infarction patients’
admission or randomization after the onset of symptoms, the
exact time of magnesium infusion after the onset of symptoms
and in relation to reperfusion were not stated. Therefore we
stratified the patients according to their admission time after
onset of symptoms (< 6 hours, 6+ hours) and this reduced het-
erogeneity of effect quite markedly with X2 falling from 55.77
(21 df ) to 16.41 (7 df ) and 1.88 (1 df ) in the two strata. No
statistical difference in early mortality was found by time of
treatment, but the remaining largely very small trials that did
not provide this information demonstrated a beneficial effect.
These findings indicate that timing of treatment is not a plau-
sible explanation for differences between ISIS-4 findings and
those of other trials.
• Turning to the use of concomitant treatments, particularly
thrombolytic therapy, there is no strong evidence that magne-
sium is better or worse than placebo in its effects on early mor-
tality. Despite stratification, heterogeneity within strata remains
suggesting that use of additional therapy is not a good expla-
nation for heterogeneity of effect. The confidence intervals of
early mortality include 1 for those patients treated with throm-
bolytics, but do not include 1 for those treated without throm-
bolytics via random effect model and in those trials where it
was not clear whether thrombolytics were or were not used. Use
of concomitant treatment such as thrombolysis might overlap
or replace the cardioprotective effects of magnesium, but this
result should be taken cautiously because of the persist hetero-
geneity after stratification.
• The dose of magnesium may be important. As ISIS-4 used only
one dose, no internal comparison can be made within this trial
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which limits the value of the stratified analyses. Early mortality
was substantially reduced in the trials using less than 75 mmol
magnesium and homogeneity was achieved between trials in
both high and low dose magnesium strata. The evidence on the
appropriate dose of magnesium (Horner 1992; Woods 1992)
was derived from a partial review of the randomized trials and is
consequently not independent of the trial findings themselves.
The issue of estimating the effects of different doses would re-
quire a new trial set up to test this specific hypothesis. If the post
hoc evidence is taken at face value, the evidence suggests that
rather than the effective dose of magnesium being the same for
everyone, the treatment is effective on average at low doses, and
ineffective at higher doses which seems implausible. However,
the major problem in judging the findings of ISIS-4 revolve
around the dose used.
For the secondary outcomes, homogeneous effects were seen for
ventricular fibrillation, II-III degree heart block, profound hy-
potension and bradycardia and heterogeneity effects were seen for
heart failure, cardiogenic shock, severe arrhythmia needing treat-
ment or Lown 2-5 and flushing. Meta-analysis showed reductions
in the odds of ventricular fibrillation, ventricular tachycardia, se-
vere arrhythmia needing treatment or Lown 2-5, but increases in
the odds of profound hypotension, bradycardia and flushing, and
no difference in the odds of heart block, cardiogenic shock com-
paring magnesium with placebo. Inconsistent results were seen for
heart failure. Fixed-effect analysis showed increases in the odds
of heart failure, but random-effects analysis showed no difference
comparing magnesium with placebo.
Careful laboratory studies, conducted since the ISIS-4 findings,
have continued to explore the role of magnesium in reducing my-
ocardial damage around the time of reperfusion, and have demon-
strated its critical nature, with any benefit lost if treatment is de-
layed (Christensen 1995; Herzog 1995; Ravn 1999). Further ex-
amination of timing, dose and concomitant treatments in clinical
patients might be rewarding.
Methodological quality
The quality of included trials was generally moderate or high, but
some studies provided limited information on the procedure of
study design, randomization, allocation concealment and blind-
ing.Weperformed a sensitivity analysis for earlymortality based on
whether adequate allocation concealment was used or not. Meta-
analysis showed that heterogeneity (X2= 32.04, P < 0.0001) was
observed for the nine trials (Gyamlani 2000; ISIS-41995;MAGIC
2000; Raghu 1999; Santoro 2000; Shechter 1990; Shechter 1995;
Smith 1986; Woods 1992) with adequate allocation concealment.
A fixed-effect model showed that there was no difference on early
mortality between the two treatment groups (OR = 1.02, 95% CI
0.96 to 1.07), while a random-effects model showed magnesium
could reduce the odds of early mortality (OR = 0.74, 95%CI 0.57
to 0.96) compared with placebo. No heterogeneity was observed
for the 13 trials that did not provide information on allocation
concealment and there was a decrease in early mortality in mag-
nesium group compared with placebo (OR 0.61, 95% CI 0.49 to
0.76). It appeared that this aspect of methodological quality did
not explain heterogeneity between trials. However, if our inability
to classify trials on grounds of timing of treatment and use of con-
comitant thrombolytic therapy are considered as quality criteria,
then there is evidence that quality of trials has had some influence
on the effects seen, with those of lower quality tending to produce
significant treatment effects.
Publication bias
Although we conducted extensive searching, we only included tri-
als that were published in English and Chinese, or published in
other languages but with an English abstract and information of
interest. Most of the included trials have small sample size except
four trials (ISIS-4 1995; MAGIC 2000; Woods 1992; Zhu 2002).
The funnel plot for all included trials is not symmetrical and po-
tential publication bias could not be avoided. We did not search
for potentially relevant trials that had not been published.
Outcomes measurement
While we do not think it is likely that biased ascertainment of
early deaths arose, the definition of clinical events such as heart
failure, cardiogenic shock, bradycardia and hypotension varied in
different trials and we recorded them based on the investigators’
judgement in trials. It is possible that some bias in ascertainment
could have arisen, particularly in smaller trials where allocation
may not have been concealed and where outcome assessors were
not blinded to treatment received.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In some parts of the world, magnesium is still viewed as an inex-
pensive, easy-to-use supplemental treatment for acute myocardial
infarction. On the basis of evidence presented here we consider
that it is unlikely that magnesium is beneficial in reducing mortal-
ity both in patients treated early and in patients treated late, and
in patients already receiving thrombolytic therapy. It is unlikely
that magnesium will reduce mortality when used at high dose of
magnesium (> 75 mmol). Magnesium treatment may reduce the
incidence of ventricular fibrillation, ventricular tachycardia, severe
arrhythmia needing treatment or Lown 2-5, but it may increase
the incidence of profound hypotension, bradycardia and flushing.
The areas of uncertainty regarding the effect of magnesium on
mortality remain the effect of low dose treatment (< 75 mmol)
and in patients not treated with thrombolysis.
Given the availability of a range of effective treatments for acute
myocardial infarction it would be preferable to ensure that these
are used than to continue using magnesium for which there is
inadequate evidence of efficacy.
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Implications for research
It seems unlikely that any further large-scale trials of magnesium
in acute myocardial infarction will be conducted in the future.
However the question of whether the dose of magnesium is im-
portant in determining efficacy when given early after symptom
onset in people not eligible for thrombolysis remains uncertain
and further trials may be needed.
P O T E N T I A L C O N F L I C T O F
I N T E R E S T
There are no potential conflicts of interest.
A C K N OW L E D G E M E N T S
We thank Shah Ebrahim for summarizing the comments on
our protocol and in-depth revising of the draft review. We also
appreciate Phil Alderson, Sally Green, Steve McDonald, Chris
Silagy in Australasian Cochrane Center, Theresa Moore, Kather-
ine Wornell, Margaret Burke in Cochrane Heart Group and Juliet
Manyemba for their helpful comments and suggestions.
S O U R C E S O F S U P P O R T
External sources of support
• China Medical Board of New York (Grant Number 98-680)
USA
Internal sources of support
• Chinese Cochrane Center, Chinese Center of Evidence-based
Medicine CHINA
• University of Bristol, Department of Social Medicine UK
• Support from West China Hospital, Sichuan University in the
form of a salary CHINA
R E F E R E N C E S
References to studies included in this review
Abraham 1987 {published data only}
Abraham AS, Rosenmann D, Kramer M, Balkin J. Zion MM. Farb-
stien H, et al. Magnesium in the prevention of lethal arrhythmias in
acute myocardial infarction. Archives of Internal Medicine 1987;147:
753–5.
Bhargava 1995 {published data only}
Bhargava B, Chandra S, Agarwal VV, Kaul U, Vashishth S, Wasir
HS. Adjunctive magnesium infusion therapy in acute myocardial
infarction. International Journal of Cardiology 1995;52:95–9.
Ceremuzynski 1989 {published data only}
Ceremuzyski L, Jurgiel R, Kulakowski P, Gebalska J. Threatening
arrhythmias in acute myocardial infarction are prevented by intra-
venous magnesium sulfate. American Heart Journal 1989;118:1333–
4.
Chen 1991 {published data only}
Chen GJ, Cui SJ, Wang JJ, Han XL, Wu H’A, Jiao H, et al. Effect
of intravenous magnesium sulfate on ventricular arrhythmia in acute
myocardial infarction. Chinese Circulation Journal 1991;6:39–40.
Feldstedt 1991 {published data only}
Feldstedt M, Boesgaard S, Bouchelouche P, Svenningsen A, Brooks
10Intravenous magnesium for acute myocardial infarction (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
L, Lech Y, et al. Magnesium substitution in acute ischaemic heart
syndromes. European Heart Journal 1991;12:1215–8.
Gyamlani 2000 {published data only}
Gyamlani G, Parikh C, Kulkarni AG. Benefits of magnesium in
acute myocardial infarction: Timing is crucial. American Heart Jour-
nal 2000;139:703.
Ising 1990 {published data only}
IsingH, Rebentisch E, Bertschat F, Gunther T. Correlations between
ventricular arrhythmias and electrolyte disturbances after acute my-
ocardial infarction. Magnesium & Trace Elements 1990;9:205–11.
ISIS-4 1995 {published data only}
Collins R, Peto R, Flather M, Parish S, Sleight P, Conway M, et
al. ISIS-4: a randomised factorial trial assessing early oral captopril,
oral mononitrate, and intravenous magnesium sulphate in 58,050
patients with suspected acute myocardial infarction. ISIS-4 (Fourth
International Study of Infarct Survival) Collaborative Group. Lancet
1995;345:669–85.
MAGIC 2000 {published data only}
McKinley S. Rational and design of the magnesium in coronaries
(MAGIC) study: A clinical trial to reevaluate the efficacy of early ad-
ministration of magnesium in acute myocardial infarction. American
Heart Journal 2000;139:10–4.
∗ The Magnesium in Coronaries (MAGIC) Trial Investigators.
Early administration of intravenous magnesium to high-risk patients
with acute myocardial infarction in the Magnesium in Coronaries
(MAGIC) Trial: a randomised controlled trial. Lancet 2002;360:
1189–96.
Morton 1984 {published data only}
Morton BC, Nair RC, Smith FM, McKibbon TG, Poznanski WJ.
Magnesium therapy in acute myocardial infarction - a double-blind
study. Magnesium 1984;3:346–52.
Morton BC, Smith FM,McKibbon TG, Poznanski WJ. The clinical
effects of magnesium sulphate treatment in acute myocardial infarc-
tion. Magnesium Bulletin 1984;4:133–6.
Nakashima 2004 {published data only}
Nakashima H, Katayama T, Honda Y, Suzuki S, Yano K. Cardio-
protective effects of magnesium sulfate in patients undergoing pri-
mary coronary angioplasty for acute myocardial infarction. Circula-
tion Journal 2004;68:23–8.
Nameki 2004 {published data only}
Nameki M, Ishibashi I, Miyazaki Y, Sakai Y, Namikawa S, Kuriyama
N, et al. Comparison between nicorandil and magnesium as an ad-
junct cardioprotective agent to percutaneous coronary intervention
in acute anterior myocardial infarction. Circulation Journal 2004;68:
192–7.
Parikka 1999 {published data only}
Parikka H, Toivonen L, Naukkarinen V, Tierala I, Pohjola-Sintonen
S, Heikkila J, et al. Decreases by magnesium of QT dispersion and
ventricular arrhythmias in patients with acute myocardial infarction.
European Heart Journal 1999;20:111–20.
Raghu 1999 {published data only}
Raghu C, Peddeswara Rao P, Seshagiri Rao D. Protective effect of
intravenous magnesium in acute myocardial infarction following
thrombolytic therapy. International Journal of Cardiology 1999;71:
209–15.
Rasmussen 1986 {published data only}
Rasmussen HS, McNair P, Norregard P, Backer V, Lindeneg O, Bal-
slev S. Intravenous magnesium in acutemyocardial infarction. Lancet
1986;1:234–6.
Rasmussen HS, Suenson M, McNair P, Norregard P, Balslev S. Mag-
nesium infusion reduces the incidence of arrhythmias in acute my-
ocardial infarction. A double-blind placebo-controlled study. Clini-
cal Cardiology 1987;10:351–6.
Santoro 2000 {published data only}
Santoro GM, Antoniucci D, Bolognese L, Valenti R, Buonamici P,
Trapani M, et al. A randomized study of intravenous magnesium in
acute myocardial infarction treated with direct coronary angioplasty.
American Heart Journal 2000;40:891–7.
Shechter 1990 {published data only}
Shechter M, Hod H, Marks N, Behar S, Kaplinsky E, Rabinowitz
B. Beneficial effect of magnesium sulfate in acute myocardial infarc-
tion. American Journal of Cardiology. American Journal of Cardiology
1990;66:271–4.
Shechter 1991 {published data only}
Shechter M, HodH.Magnesium therapy in aged patients with acute
myocardial infarction. Magnesium Bulletin 1991;13(1):7–9.
Shechter 1995 {published data only}
Shechter M,HodH, Chouraqui P, Kaplinsky E, Rabinowitz B. Mag-
nesium therapy in acute myocardial infarction when patients are not
candidates for thrombolytic therapy. American Journal of Cardiology
1995;75:321–3.
Singh 1990 {published data only}
Singh RB, Singh NK, Niaz MA, SharmaJP. Effect of treatment with
magnesium and potassium on mortality and reinfarction rate of pa-
tients with suspected acute myocardial infarction. International Jour-
nal of Clinical Pharmacology & Therapeutics 1996;34:219–25.
Singh RB, Sircar AR, Rastogi SS, Garg V. Magnesium and potassium
administration in acute myocardial infarction. Magnesium & Trace
Elements 1990;9:198–204.
Smith 1986 {published data only}
Smith LF, Heagerty AM, Bing RF, Barnett DB. Intravenous infusion
of magnesium sulphate after acute myocardial infarction: effects on
arrhythmias and mortality. International Journal of Cardiology 1986;
12:175–83.
Thogersen 1995 {published data only}
Thogersen AM, Johnson O, Wester PO. Effects of intravenous mag-
nesium sulphate in suspected acute myocardial infarction on acute
arrhythmias and long-term outcome. International Journal of Cardi-
ology 1995;49:143–51.
Thogersen AM, Johnson O, Wester PO. Effects of magnesium in-
fusion on thrombolytic and non-thrombolytic treated patients with
acutemyocardial infarction. International Journal of Cardiology 1993;
39:13–22.
Urek 1996 {published data only}
Urek R, Halle J, Frank B, Goles T, Tomici D, Mirat J, et al. Intra-
venous magnesium in acute myocardial infarct [Intravenski magnezij
u akutnom infarktu miokarda]. Lijecnicki Vjesnik 1996;118:279–81.
11Intravenous magnesium for acute myocardial infarction (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Woods 1992 {published data only}
Roffe C, Fletcher S, Woods KL. Investigation of the effects of intra-
venous magnesium sulphate on cardiac rhythm in acute myocardial
infarction. British Heart Journal 1994;71:141–5.
Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium
sulphate in suspected acute myocardial infarction: results of the sec-
ond Leicester IntravenousMagnesium InterventionTrial (LIMIT-2).
Lancet 1992;339:1553–8.
Wu 1992 {published data only}
Wu YL, Yang P, Su YP, Kang MY, Xu LF. Effect of magnesium in
acute myocardial infarction. Chinese Circulation Journal 1992;7:434.
Zhu 2002 {published data only}
Zhu WL. A multi-center randomized clinical trial to evaluate the
efficacy of early administration of magnesium in acute myocardial
infarction. Chinese Journal of Cardiology 2002;30:82–5.
References to studies excluded from this review
Abraham 1994
Abraham AS, Balkin J, Rosenmann D, Ilan M, Klutstein M, Zion
MM. Long-term follow-up after acute myocardial infarction in pa-
tients randomized to treatment with intravenous magnesium or in-
travenous propranolol in the acute phase. Magnesium Research 1994;
7:273–6.
Balkin 1994
Balkin J, Rosenmann D, Ilan M, Klutstein M, Zion MM, Abraham
AS. A prospective randomized trial of intravenous magnesium versus
intravenous propranolol in acute myocardial infarction. Magnesium
Research 1994;7:267–71.
Flather 1994
Flather M, Pipilis A, Collins R, Budaj A, Hargreaves A, Kolettis T, et
al. Randomized controlled trial of oral captopril, of oral isosorbide
mononitrate and of intravenous magnesium sulphate started early
in acute myocardial infarction: safety and haemodynamic effects.
ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study
Investigators. European Heart Journal 1994;15:608–19.
Leone 1991
Leone A, Mori L, Bertanelli F, Fabiano P. Life-threatening arrhyth-
mias after intravenous lidocaine alone or with magnesium in my-
ocardial infarction complicated by ventricular fibrillation. Singapore
Medical Journal 1991;32:169–70.
Petri 1985
Petri M Zezulka A, et al. Intracellular and plasma magnesium af-
ter acute myocardial infarction [abstract]. Clinical Science 1985;69
(Suppl 12):69P.
Rasmussen 1988
Rasmussen HS, Gronbaek M, Cintin C, Balslov S, Norregard P, Mc-
Nair P. One-year death rate in 270 patients with suspected acute my-
ocardial infarction, initially treated with intravenous magnesium or
placebo. Clinical Cardiology 1988;11:377–81.
Shechter 2003
Shechter M, Hod H, Rabinowitz B, Boyko V, Chouraqui. Long-
term outcome of intravenous magnesium therapy in thrombolysis.
Cardiology 2003;99:205–10.
Smith 1985
Smith L Heagerty A, et al. Magnesium sulphate infusion after acute
myocardial infarction: effects on arrhythmias and mortality. Clinical
Science 1985;68(Suppl 11):56P–57P.
Su 1997
Su ZD, Zhong YY, Zhou JZ, Chang YF, Dai HQ. Influence of mag-
nesium sulfate on QTc dispersion in earlier period of patient with
acute myocardial infarction. Chinese Circulation Journal 1997;12:
296.
Sun 1990
SunGH, Hou JM, Wang ZP, Chen ML, Sui F, Lin YD, et al. Effect
of magnesium on ventricular arrhythmia after acute myocardial in-
farction. Chinese Circulation Journal 1990;5:303–5.
Woods 1994
Woods KL, Fletcher S. Long-term outcome after intravenous mag-
nesium sulphate in suspected acute myocardial infarction: the sec-
ond Leicester IntravenousMagnesium InterventionTrial (LIMIT-2).
Lancet 1994;343:816–9.
Xu 1990
Xu CJ, Wang PR, Shao JH. Therapeutic effect of magnesium sulfate
on earlier period of acute myocardial infarction. Chinese Journal of
Cardiology 1990;18:330.
References to studies awaiting assessment
Pereira 1990
Pereira D, Pereira TG, Rabacal C, Carvalho E, Linder J, Afonso JS,
et al. Effect of intravenous administration of SO4Mg in the acute
phase of myocardial infarct [Efeito da administracao de SO4Mg por
via intra-venosa na fase aguda do enfarte do miocardio]. Revista Por-
tuguesa de Cardiologia 1990;9:205–10.
Rekosz 1996
Rekosz J. Magnesium prevents recurrent ischaemia in thrombol-
ysed patients with acute myocardial infarction. A preliminary report
[Magnez zapobiega nawrotom niedokrwienia po leczeniu fibrynoli-
tycznym ostrego zawalu serca]. Kardiologia Polska 1996;44:20–4.
Spisak 1994
Spisak V. Treatment of acute myocardial infarction with magnesium
[Liecba akutneho infarktu myokardu magneziom]. Vnitrni Lekarstvi
1994;40:649–53.
Yavelov 1995a
Yavelov IS, Smetanina IN, Averkov OV, Gratsiansky NA. Effect of
intravenous magnesium infusion on global left ventricular systolic
function and clinical signs of heart failure in high risk patients with
suspected acute myocardial infarction. A double blind placebo-con-
trolled study. Kardiologiya 1995;35:28–39.
Yavelov 1995b
Yavelov IS, Averkov OV, Gratsiansky NA, Logutov Yu A, Semenova
VM. Intravenous infusion of magnesium sulphate does not affect
inhospital mortality of patients with suspectedmyocardial infarction.
Kardiologiya 1995;35:54–6.
Additional references
Antman 1995a
Antman EM. Randomized trials of magnesium in acute myocardial
infarction: big numbers do not tell the whole story. American Journal
of Cardiology 1995;75:391–3.
12Intravenous magnesium for acute myocardial infarction (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Antman 1995b
Antman EM. Magnesium in acute MI: timing is critical. Circulation
1995;92:2367–72.
Antman 1996
Antman EM.Magnesium in acutemyocardial infarction: overview of
available evidence. American Heart Journal 1996;132(2 Pt 2 Suppl):
487–94.
Borchgrevink 1989
Borchgrevink PC, Bergan AS, Bakoy OE, Jynge P. Magnesium and
reperfusion of ischemic rat heart as assessed by 31P-NMR. American
Journal of Physiology 1989;256:H195–H204.
Christensen 1995
Christensen CW, Rieder MA, Silverstein EL, Gencheff NE. Magne-
sium sulfate reduces myocardial infarct size when administered be-
fore but not after coronary reperfusion in a caninemodel. Circulation
1995;92:2617–21.
Egger 1994
Egger M, Smith GD. Magnesium and myocardial infarction. Lancet
1994;343:1285–8.
Egger 1995
Egger M. Misleading meta-analysis: lessons from “an effective, safe,
simple” intervention that wasn’t. BMJ 1995;310:752–4.
Egger 1997
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphic test. BMJ 1997;315:629–34.
Ferrari 1986
Ferrari R, Albertini A, Curello S, Ceconi C, Di Lisa F, Raddino R, et
al. Myocardial recovery during post-ischaemic reperfusion: effects of
nifedipine, calcium and magnesium. Journal of Molecular & Cellular
Cardiology 1986;18:487–98.
Galloe 1994
Galloe A, Graudal N. Magnesium and myocardial infarction. Lancet
1994;343:1286–7.
Haverkamp 1988
Haverkamp W, Hindricks G, Keteller T, Allberty D, Weithold D,
Gulker H. Prophylactic antiarrhythmic and antifibrillatory effects of
intravenous magnesium sulphate during acute myocardial ischaemia.
European Heart Journal 1988;9:228.
Hedblad 1997
Hedblad B, Janzon L, Johansson BW, Juul-Moller S. Survival and
incidence of myocardial infarction in men with ambulatory ECG-
detected frequent and complex ventricular arrhythmias. European
Heart Journal 1997;18:1787–95.
Herzog 1995
Herzog WR, Schlossberg ML, MacMurdy KS, Edenbaum LR, Ger-
ber MJ, Vogel RA, et al. Timing of magnesium therapy affects exper-
imental infarct size. Circulation 1995;92:2622–6.
Higgins 2002
Higgins JP, Spiegelhalter DJ. Being sceptical about meta-analyses: a
Bayesian perspective on magnesium trials in myocardial infarction.
International Journal of Epidemiology 2002;31:96–104.
Horner 1992
Horner SM. Efficacy of intravenous magnesium in acute myocar-
dial infarction in reducing arrythmias and mortality. Meta-analysis
of magnesium in acute myocardial infarction. Circulation 1992;86:
774–9.
Mroczek 1977
MroczekWj, LeeWR, DavidovME. Effect of magnesium sulfate on
cardiovascular hemodynamics. Angiology 1977;28:720–4.
Ravn 1999
RavnHB,Moeldrup U, Brookes CI, Ilkjaer LB,White P, ChewM, et
al. Intravenous magnesium reduces infarct size after ischemia/reper-
fusion injury combined with a thrombogenic lesion in the left ante-
rior descending artery. Arteriosclerosis, Thrombosis & Vascular Biology
1999;19:569–74.
Teo 1991
Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous
magnesium in suspected acute myocardial infarction: overview of
randomised trials. BMJ 1991;303:1499–1503.
Tzivoni 1990
Tzivoni D, Keren A. Suppression of ventricular arrhythmias by mag-
nesium. American Journal of Cardiology 1990;65:1387–99.
Vigorito 1991
VigoritoC,GiordanoA, FerraroP, AcanforaD,DeCaprioL,Naddeo
C, et al. Hemodynamic effects of magnesium sulfate on the normal
human heart. American Journal of Cardiology 1991;67:1435–7.
Watson 1986
Watson KV, Moldow CF, Ogburn PL, Jacob HS. Magnesium sul-
fate: rationale for its use in pre-eclampsia. Proceedings of the National
Academy of Sciences of the United States of America 1986;83:1075–8.
Woods 1991
Woods KL. Possible pharmacological actions of magnesium in acute
myocardial infarction. British Journal of Clinical Pharmacology 1991;
32:3–10.
Woods 1995
Woods KL. Mega-trials and management of acute myocardial infarc-
tion. Lancet 1995;346:611–4.
Yusuf 1993
Yusuf S, Teo KK, Woods K. Intravenous magnesium in acute my-
ocardial infarction. An effective, safe, simple and inexpensive inter-
vention. Circulation 1993;87:2043–46.
∗Indicates the major publication for the study
13Intravenous magnesium for acute myocardial infarction (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
T A B L E S
Characteristics of included studies
Study Abraham 1987
Methods Randomization: computer-generated random number, similar solutions being prepared for each patients.
Blinding: double-blind (patients and physicians), placebo-controlled.
Follow-up: complete.
Participants 94 patients with AMI were immediately transferred to the CCU and entered into the study; placebo group:
46, mean age 61.1y, magnesium group: 48, mean age 64.2 y.
Interventions Treatment group: 2.4g of magnesium sulfate in 50 ml of 5% glucose solution.
Control group: 50 ml of 5% glucose solution alone.
Treatment duration: intravenously over a 20 minutes period for 3 days and monitor 72-h period.
Outcomes Appearance of ventricular triplets, R-on-T phenomenon, or ventricular tachycardia or fibrillation and side
effects, measurement of lymphocyte K and Mg.
Notes
Allocation concealment B – Unclear
Study Bhargava 1995
Methods Randomization: stratified randomization.
Blinding: not stated, placebo controlled.
Follow-up: complete.
Participants 78 consecutive proven patients with chest pain of 1-6h were randomized. 40 in treatment and 38 in control
groups.
Interventions Treatment group: 8 mmol magnesium sulphate over 5 min followed by 65 mmol over 24-h infusion.
Control group: isotonic saline infusion.
Duration of symptoms before randomization into Mg and placebo groups was the same(Mg: 5.3+/-3.3h vs
placebo: 5.6+/-3.2h)
Outcomes Arrhythmia: ventricular premature beats, ventricular tachycardia, ventricular fibrillation, supraventricular
tachyarrhythmias, bradycardia and asystole.
All cardiac events: reinfarction, mortality and coronary bypass surgery during hospital stay and at the end of
28 days
Notes
Allocation concealment B – Unclear
Study Ceremuzynski 1989
Methods Randomization: no detail.
Blinding: not stated.
Follow-up: complete.
Participants 48 patients with AMI within 12 h from onset of symptoms were randomly assigned to either control group
(n = 23, age 43-81y), or magnesium group (n = 25, age 44-77y).
Interventions Treatment group: 8 g MgSO4 in 500 mL 15% glucose for 24 h intravenously plus conventional treatment.
Control group: conventional treatment.
Outcomes Threatening arrhythmia (VT: >=3 consecutive VPC with a rate of > 120/min) and inhospital mortality.
Notes
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Characteristics of included studies (Continued )
Allocation concealment B – Unclear
Study Chen 1991
Methods Randomization: no detail.
Blinding: outcome assessor was blinded to the allocation.
Follow-up: complete.
Participants 62 patients with AMI was randomly allocated to Mg (n+32, mean age: 54.5 y) or placebo (n = 30, mean
age: 51.1 y) groups. All patients was admitted within 24 h from onset of symptoms.
Interventions Treatment group: MgSO4 2g/day for 3 days.
Placebo group: 5% glucose.
Outcomes Arrhythmia for 72 h.
Notes
Allocation concealment B – Unclear
Study Feldstedt 1991
Methods Randomization: block randomization.
Blinding: double-blinded, placebo-controlled trial.
Follow-up: 13 in Mg and 7 in placebo groups were withdraw without stated the reasons, intention-to-treat
for in-hospital mortality.
Participants 298 patients, aged 75 y or less, with suspected AMI less than 8 h were randomized to either magnesium (n
= 150, mean age = 59, range 28-75, confirmed AMI = 83) or placebo (n = 148, mean age = 61 y, range 41-
75, confirmed AMI = 78) group.
Interventions Treatment group: continuous infusion of 80 mmol magnesium chloride in 1000 mL dextrose
Control group: matching placebo.
Outcomes In-hospital death on the principle of intention to treat.
Notes
Allocation concealment B – Unclear
Study Gyamlani 2000
Methods Randomization: random patients numbers generated with the FoxPro database application, randomization
codes were held by the pharmacy department and independent statistician only.
Blinding: double-blind, placebo-controlled, identical treatment packs for trial and placebo treatments were
manufactured in the production unit of the pharmacy service.
Follow-up: complete
Participants 100 patients with proven AMI were randomly allocated to Mg group (n = 50, mean age: 56.1+/-12.28) or
placebo group (n = 50, mean age: 57+/-11). All patients were admitted with symptoms less than 6 h. No lost
to follow-up.
Interventions Treatment group: 12g (50 mmol) in the first 24h, 3g (12 mmol) in the second 24h.
Placebo group:
equal volume of isotonic glucose.
Mg was used within 2h after admission and within 30 minutes of thrombolytic therapy.
Outcomes Serum magnesium, CK, all arrhythmia and conduction abnormalities, death within 4 weeks.
Notes
Allocation concealment A – Adequate
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Characteristics of included studies (Continued )
Study ISIS-4 1995
Methods Randomization: Entry to the study was by telephone to central 24 h randomisation services. Baseline details
about the patients were to be recorded, either directly onto computer or onto computer-generated randomi-
sation lists, before a specific numbered trial treatment pack was to be allocated.
Blinding: open control, no placebo was given
Follow-up: 1.7% was missing for both groups, analysis was based on intention-to-treat.
Participants 58,050 patients entering 1086 hospitals up to 24 h (median 8 h) after the onset of suspected acute myocardial
infarction with no clear contraindications to the study treatments were randomised in a “2x2x2 factorial”
study. 29011(confirmed AMI 26,264) in magnesium and 29,030 (confirmed AMI 26,261) in control group.
Interventions Treatment group: 24 h of intravenous magnesium sulphate (8 mmol initial bonus injection over about 15
minutes followed by 72 mmol in about 50 mLinfused over 24 h)
Control group: with no placebo infusion being given.
Outcomes Mortality in first 5 weeks and other clinical events in hospital, e.g. ventricular fibrillation, II-III degree heart
block, heart failure, cardiogenic shock, hypotension, bradycardia, flushing.
Notes
Allocation concealment A – Adequate
Study Ising 1990
Methods Randomization: no detail.
Blinding: not stated.
Follow-up: complete.
Participants 42 patients with AMI. Magnesium group: 22 (mean age = 56); control group: 20 (mean age = 56).
Interventions Treatment group: 81 mval/day magnesium sulphate infusion 13+/-9h after the onset of severe pain for 3 days
Control group: 80 mval/day NaCl infusion for 3 days.
Outcomes Serious arrhythmia, i.e. number of patients with couplets and ventricular tachycardia.
Notes
Allocation concealment B – Unclear
Study MAGIC 2000
Methods Randomization: permuted block randomisation design, stratified by clinical center and stratum (stratum 1
with reperfusion therapy, stratum 2 without reperfusion therapy) and with a central interactive telephone
voice response system.
Blinding: double-blind, matched sterile water as placebo
Follow-up: 3 in Mg and 2 in placebo groups were lost. Data analysis was based on intention-to-treat.
Participants 1924 in stratum 1 and 4289 in stratum 2 were randomised. 3113 inMg and 3100 in placebo groups [median
age: 70 (63-76) vs 70 (63-75)]. All patients received the blinded study drug within 6 h of onset of symptoms.
Interventions Treatment group: 2 g intravenous bolus of MgSO4 over 15 minutes, followed by a 17 g infusion of MgSO4
over 24 h.
Placebo group: blinded, matched intravenous bolus and 24 h infusion of sterile water.
Outcomes Primary endpoint: all-cause mortality within 30 days.
Secondary endpoints: treatment for heart failure, defibrillation of ventricular fibrillation or sustained ven-
tricular tachycardia and treatment with a temporary pacemaker.
Notes
Allocation concealment A – Adequate
Study Morton 1984
Methods Randomization: random number table.
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Characteristics of included studies (Continued )
Blinding: double-blind. Neither patients nor medical or nursing staff knew as to the allocation to the therapy.
Follow-up: five were excluded from analysis.
Participants 76 patients with AMI within 8 h of onset were included.
Treatment group: 40, age 54+/-1.6;
Control group: 57+/-1.4. Duration of symptoms prior to entry (hrs) is 5.3+/-0.2 and 4.7+/-0.3 respectively.
Interventions Treatment group: 36 h intravenous infusion of magnesium sulphate (0.75 mEq/kg/body weight/12 h).
Control group: saline solution infusion.
Outcomes Mortality within 2 days, dysrhythmias, blood pressure, heart rate and signs of heart failure.
Notes This paper was also published in Magnesium 1984;3:346-352 by Morton et al. Data were collected from
both papers
Allocation concealment B – Unclear
Study Nakashima 2004
Methods Randomization: no detail.
Blinding: single-blind.
Follow-up: complete.
Participants 180 patients with successful PCI were randomly assigned. 89 in Mg and 91 in control groups with similar
characteristics of age (67+/-11 vs 69+/-11), sex and time to admission (3.0+/-2.2 vs 3.1+/-2.4) after onset.
Interventions Treatment group: bolus injection of 8 mmol of magnesium followed by an infusion of 24 mmol over 24 h.
Control group: equivalent amount of normal saline.
Other treatment: all patients underwent PCI, aspirin, heparin, nicorandil (4 mg/h for 3 days) use.
Outcomes In-hospital mortality and clinical complications including death, heart failure, cardiogenic shock and ven-
tribular fibrillation, left ventribular function
Notes
Allocation concealment B – Unclear
Study Nameki 2004
Methods Randomization: no detail.
Blinding: not clear.
Follow-up: 6 patients did not underwent LVG, left 34 patients duing 3 months follow-up.
Participants 40 patients with successful PCI were randomly assinged to nicorandil (13), Mg (13) and control groups (14)
with similar baseline characteristics of age, sex.
Interventions Treatment group:
- nicorandil: 4 mg iv and 4 mg intracoronarily before reperfusion, followed by iv infusion at 4 mg/h for the
subsequent 24 h.
- magnesium: 10 mmol iv before reperfusion, followed by iv infusion at 0.4 mmol/h for the subsequent 24
h.
Control: neither nicorandil nor magnesium was given.
Other treatment: similar.
Outcomes Left ventriculography was performed to measure EDVI, ESVI, EF, RWM.
Reperfusion phenomena: chest pain, blood pressure decrease, ST elevation and reperfusion arrythmia
Notes
Allocation concealment B – Unclear
Study Parikka 1999
Methods Randomization: no detail.
Blinding: double-blind placebo controlled.
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Characteristics of included studies (Continued )
Follow-up: 5 in first 24 h and 15 at discharge were lost, no detail.
Participants 59 consecutive patients with < 12 h from onset of chest pain AMI was randomized to magnesium (n = 31,
age 30-73, mean 60). or placebo (n = 26, age 36-74, mean=59 ) group.
Interventions Treatment group: 8mmol MgSO4 in 10 min, 62 mmol in 24h.
Placebo group: NaCl.
Other treatment, e.g. beta-blocker, aspirin, ACE inhibitors, diuretics determined by attending clinician,
thrombolytic treatment if appropriate start preceded the study infusion.
Outcomes Number of supraventricular and ventricular premature beats, tachycardia, heart rate variability and conduc-
tion disturbance recorded by 24 h Holter prior to infusion and on 7th to 14th day in hospital. Heart failure
diagnosed by radiology.
Notes
Allocation concealment B – Unclear
Study Raghu 1999
Methods Randomization: computerized randomization program.
Blinding: double-blind, placebo controlled.
Follow-up: complete.
Participants 350 confirmed AMI < 6 h from the onset of symptoms were randomized either to treatment (n = 181, mean
age 53.1+/-10.8) or to control (n = 169, mean age 52.9+/-11.0).
Interventions Treatment group: 18 g (75.6 mmol) of Mg sulphate over 24 h
Control group: equivalent amount of saline. Mg were started immediately after completion of thrombolytic
therapy.
Outcomes 30 day of mortality, tachycardia arrhythmia, reinfarction, post-infarct angina and flushing.
Notes
Allocation concealment A – Adequate
Study Rasmussen 1986
Methods Randomization: no detail.
Blinding: double-blind, placebo-controlled.
Follow-up: complete.
Participants 273 patients with suspected AMI were randomised to either Mg or placebo group. Of 130 patients with
proven AMI, 56 (mean age 64.6, range 39-89) received Mg and 74(mean age 67.6, range 40-91) received
placebo.
Interventions Treatment group: 50 mmol MgCl2 during the first 24 h, 12 mmol during the second 24 h.
Control group: isotonic glucose.
Outcomes Mortality during first 4 weeks, proportion of arrhythmia needing treatment.
Notes Another report based on the same group of patients, but mainly focused on the incidence of arrhythmia was
published by clin. Cariol. 1987;10:351-356. Data were collected from both reports.
Allocation concealment B – Unclear
Study Santoro 2000
Methods Randomization: random allocation was generated by computer and codes remained concealed until data
collection and analysis were finished.
Blinding: outcome assessor were blinded, placebo-controlled trial.
Follow-up: analysis was made on an intention-to-treat basis.
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Characteristics of included studies (Continued )
Participants 150 patients were randomized to intravenous MgSO4 group (n = 75, age: 60+/-11) or placebo (n = 75, age:
60+/-12). All patients were admitted to CCU within 6h of symptom onset.
Interventions Treatment group: 7 g (28 mmol) with 5 h.
Placebo group: matching saline solution.
Treatment was started immediately after randomization before all patients receiving angioplasty.
Outcomes Primary endpoints: infarct zone wall motion score index at 30 days (infarct size).
Secondary endpoints: CK peak values, VF or VT (> 6 consecutive beats > 120/min), death, heart failure
during 30 days follow-up
Notes
Allocation concealment A – Adequate
Study Shechter 1990
Methods Randomization: no detail.
Blinding: double-blind, placebo-controlled.
Follow-up: complete.
Participants 115 consecutive patients with admission diagnosis of AMI were randomized. Of them, 103 with proven
AMI were analyzed. 50 in magnesium and 53 in control groups. (mean age: 64 y vs 63 y; time from pain to
treatment: 5.3+/-3.3 vs 5.3+/-3.0 respectively).
Interventions Treatment group: 22 g (91.6 mmol) within 48 h (67 mmol within first 24 h).
Control group: isotonic glucose.
No prophylactic antiarrhythmic therapy, thrombolytic therapy was not routinely available.
Outcomes In-hospital mortality and morbidity, e.g. arrhythmia, conduction disturbance, heart failure.
Notes
Allocation concealment B – Unclear
Study Shechter 1991
Methods Randomization: no detail.
Blinding: double-blind, placebo-controlled.
Follow-up: complete.
Participants 159 patients with documented AMI were randomized. Among 46 were older than 70 y (range:72-89, mean:
76+/-4) and analyzed. 21 in magnesium and 25 in control groups.
Interventions Treatment group: 22 g (91.6 mmol) within 48 h (67 mmol within first 24 h).
Control group: isotonic glucose.
No prophylactic antiarrhythmic therapy, thrombolytic therapy was not routinely available.
Outcomes Arrhythmia, conduction disturbance, heart failure and mortality.
Notes
Allocation concealment B – Unclear
Study Shechter 1995
Methods Randomization: computerized randomization program (EPISTAT).
Blinding: double-blind, placebo-controlled trial.
Follow-up: complete. Analysis only on documented 159 patients.
Participants 215 patients suspected with AMI and considered unsuitable candidates for thrombolysis were randomized.
194 patients with confirmed AMI were analyzed. 96 in magnesium and 98 in placebo groups (age: 66+/-12
vs 66+/-13; time from pain to treatment: 7.0+/-4.3, 7.1+/-2.2).
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Characteristics of included studies (Continued )
Interventions Treatment group: 22 g (91.6mmol) within 48 h (67mmol within first 24 h). Control group: isotonic glucose.
No prophylactic antiarrhythmic therapy and no thrombolytic therapy.
Outcomes Arrhythmia, conduction disturbance, congestive heat failure, and hospital mortality.
Notes
Allocation concealment A – Adequate
Study Singh 1990
Methods Randomization: randomized by the nurse and residents to receive solution marked in identical bottles.
Blinding: double-blind, placebo-controlled trial.
Follow-up: 3 in Mg and 2 in placebo groups were lost and analysis was based on intention to treat.
Participants 326 patients suspected with AMI (264 confirmed and analyzed), admitted to the hospital within 8-12h of
the onset of MI, were randomly assigned to one of the 4 groups.
Interventions Treatment group: 5 g (8.12 mmol) of MgSO4 daily for 4 days.
Placebo group: 2% dextrose solution for 3 days.
Outcomes 4 weeks complications (hypotension, pump failure with shock, arrhythmias requiring treatment) and mor-
tality
Notes The combination of short- and long-term effects were also published in International Journal of Clinical
Pharmacology and Therapeutics. 1996;34(5):219-225. Data of mortality from Singh 1996, data of compli-
cations from singh1990.
Allocation concealment A – Adequate
Study Smith 1986
Methods Randomization: the solutions were prepared in identical vials by the hospital pharmacy.
Blinding: double-blind
Follow-up: 6 in Mg and 9 in placebo groups were withdrawn, only documented patients were included in
the analysis.
Participants 400 patients with suspected AMI were admitted. Among 200 were confirmed and included in the analysis.
92 in magnesium and 93 in placebo groups (mean age: 59.7+/-0.9 vs 58.4+/-2.2).
Interventions Treatment group: 65 mmol MgSO4 given over 24 h.
Placebo group: Saline.
Outcomes Episodes of ventricular tachyarrhythmia and mortality within 24h.
Notes
Allocation concealment A – Adequate
Study Thogersen 1995
Methods Randomization: stratified randomization by fibrinolytic therapy or not.
Blinding: double-blind.
Follow-up: 12 in Mg and 11 in placebo groups were withdrawn and analysis was intention to treat.
Participants 252 patients with suspected AMI were included. 130 in Mg and 122 in placebo groups (mean age: 67+/-11
vs 67+/-11; admission time: 9.8+/-21.8 vs 8.1+/-9.1; confirmed AMI: 57 vs 60; thrombolytic treatment: 39
vs 38).
Interventions Treatment group: 50 mmol within 24 h.
Placebo group: isotonic NaCl.
Outcomes All clinically important arrhythmias after the first 24 h and all serious cardiac events (AMI, coronary bypass
surgery, death). Unfortunately, most of the data were combination of short and follow-up effect. Analysis
was based on intention to treatment.
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Characteristics of included studies (Continued )
Notes Another report based on the same group of patients was published in International Journal of Cardiology
1993;39:13-22. Data were collected from both reports.
Allocation concealment B – Unclear
Study Urek 1996
Methods Randomization: no detail.
Blinding: double blind placebo controlled study.
Follow-up: complete.
Participants 61 patients with documented AMI. 31 in Mg and 30 in placebo groups (mean age: 60.5 vs 63.2; time from
onset of pain to treatment: < 12 h).
Interventions Treatment group: 17 g MgSO4 with first 24 h.
Placebo group: saline.
Outcomes Severe arrhythmias, hospital mortality and conduction disturbances.
Notes Because of language difficulty, detail information need help from interpreter.
Allocation concealment B – Unclear
Study Woods 1992
Methods Randomization: computer-generated blocked randomization schedule and codes were held by the pharmacy
department and the independent statistician only.
Blinding: double blind, placebo controlled study by using identical treatment packs.
Follow-up: 9 in Mg and 7 in placebo groups were lost with reasons, but excluded the 28-day mortality
analysis. Intention-to-treat analysis was stated.
Participants 2316 patients with suspected AMI in the preceding 24h were included. 1159 in Mg and 1157 in placebo
groups (mean age: 61.4+/-11.4 vs 62.2+/-11.5; confirmed AMI: 754 vs 754; number of patients treated with
thrombolysis: 419 vs 402).
Interventions Treatment group: 8 mmol over 5 min, 65 mmol over 24h.
Placebo group: physiological saline.
Outcomes 28-day mortality, morbidity e.g. LVF, hypotension, heart block bradycardia, tachyarrhythmias.
Notes Another report based on same group of patient was published on Br Heart J 1994;71:141-145.
Allocation concealment A – Adequate
Study Wu 1992
Methods Randomization: no detail was given.
Blinding: not stated.
Follow-up: not stated.
Participants 248 suspected AMI were randomized and 227 were confirmed and included in the study. 125 in treatment
and 102 in placebo groups.
Interventions Treatment group: 2.5 g MgSO4 once or twice a day for 7-14 days.
Placebo group: conventional treatment. Conventional study was equal in two groups.
Outcomes Arrhythmia and mortality within 4 weeks.
Notes
Allocation concealment B – Unclear
Study Zhu 2002
Methods Randomization: stratified randomization, multi-center.
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Blinding: open trial.
Follow-up: complete.
Participants 3179 eligible AMI patients in proceeding 24 h were randomized to either treatment (n = 1691, admission
time = 9.04 h, age = 62.4+/-11.0) or control (n = 1488, admission time = 9.01, age = 63.2+/-11.0) group.
809 in treatment group and 668 in control group received thrombolysis.
Interventions Treatment group: 100 mL (4 g) potassium-magnesium aspartate IV. for the first day, 50 ml for rest 4 days
plus routine AMI treatment.
Control group: same routine AMI treatment as treatment group.
Outcomes Mortality rate within 28 days, arrhythmia.
Notes
Allocation concealment B – Unclear
AMI: acute myocardial infarction
CCU: coronary care unit
h: hours
K: potassium
Mg: magnesium
MgCl2: magnesium chloride
MgSO4: magnesium sulfate
NaCl: sodium chloride
PCi: percutaneous coronary intervention
y: years
Characteristics of excluded studies
Study Reason for exclusion
Abraham 1994 Compare magnesium with propranolol.
Balkin 1994 Compare magnesium with propranolol.
Flather 1994 Pilot study of ISIS-4.
Leone 1991 Not indicated as RCT by the authors.
Petri 1985 Only abstract.
Rasmussen 1988 Long term effect study.
Shechter 2003 Long term effect study.
Smith 1985 Only abstract.
Su 1997 Published as abstract without available data.
Sun 1990 Claimed to be an RCT, but a retrospective study.
Woods 1994 Long term effect.
Xu 1990 Published as abstract without available data.
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A N A L Y S E S
Comparison 01. Magnesium vs placebo on mortality
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 mortality by time of admission 23 72472 Odds Ratio (Fixed) 95% CI 0.99 [0.94, 1.04]
02 mortality by use of
thrombolytic therapy
25 71434 Odds Ratio (Fixed) 95% CI 0.99 [0.93, 1.04]
03 mortality by dose of magnesium 22 72476 Odds Ratio (Fixed) 95% CI 0.99 [0.94, 1.04]
Comparison 02. Magnesium vs placebo on morbidity
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Ventricular fibrillation 11 62392 Odds Ratio (Fixed) 95% CI 0.88 [0.81, 0.96]
02 Ventricular tachycardia 9 1187 Odds Ratio (Fixed) 95% CI 0.45 [0.31, 0.66]
03 II-III heart block 9 67338 Odds Ratio (Fixed) 95% CI 1.05 [0.97, 1.14]
04 Heart failure 14 68140 Odds Ratio (Fixed) 95% CI 1.07 [1.03, 1.11]
05 Profound hypotension 5 60668 Odds Ratio (Fixed) 95% CI 1.13 [1.09, 1.19]
06 Cardiogenic shock 12 62334 Odds Ratio (Fixed) 95% CI 1.07 [0.99, 1.16]
07 severe arrhythmia needing
treatment
10 7353 Odds Ratio (Fixed) 95% CI 0.72 [0.60, 0.85]
Comparison 03. Magnesium vs placebo on side effect
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Bradycardia 4 60574 Odds Ratio (Fixed) 95% CI 1.49 [1.26, 1.77]
02 Flushing 5 58744 Odds Ratio (Fixed) 95% CI 20.78 [12.90, 33.46]
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G R A P H S A N D O T H E R T A B L E S
Figure 01.
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Analysis 01.01. Comparison 01 Magnesium vs placebo on mortality, Outcome 01 mortality by time of
admission
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 01 Magnesium vs placebo on mortality
Outcome: 01 mortality by time of admission
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
01 admission time <6 hrs
Abraham 1987 1/48 1/46 0.0 0.96 [ 0.06, 15.77 ]
Gyamlani 2000 2/50 10/50 0.4 0.17 [ 0.03, 0.81 ]
ISIS-4 1995 928/11675 880/11648 29.9 1.06 [ 0.96, 1.16 ]
MAGIC 2000 475/3113 472/3100 14.8 1.00 [ 0.87, 1.15 ]
Morton 1984 1/40 2/36 0.1 0.44 [ 0.04, 5.02 ]
Raghu 1999 6/169 18/181 0.6 0.33 [ 0.13, 0.86 ]
Santoro 2000 0/75 1/75 0.1 0.33 [ 0.01, 8.20 ]
Woods 1992 90/1150 118/1150 4.0 0.74 [ 0.56, 0.99 ]
Subtotal (95% CI) 16320 16286 49.9 1.00 [ 0.93, 1.08 ]
Total events: 1503 (Treatment), 1502 (Control)
Test for heterogeneity chi-square=16.41 df=7 p=0.02 I² =57.4%
Test for overall effect z=0.05 p=1
02 admission time >= 6 hrs
ISIS-4 1995 1288/17333 1223/17390 41.7 1.06 [ 0.98, 1.15 ]
Singh 1990 6/81 11/81 0.4 0.51 [ 0.18, 1.45 ]
Subtotal (95% CI) 17414 17471 42.1 1.06 [ 0.97, 1.15 ]
Total events: 1294 (Treatment), 1234 (Control)
Test for heterogeneity chi-square=1.88 df=1 p=0.17 I² =46.8%
Test for overall effect z=1.32 p=0.2
03 admission time not specified or mixture
Bhargava 1995 3/40 3/38 0.1 0.95 [ 0.18, 5.00 ]
Ceremuzynski 1989 1/25 3/23 0.1 0.28 [ 0.03, 2.88 ]
Feldstedt 1991 10/150 8/148 0.3 1.25 [ 0.48, 3.26 ]
Nakashima 2004 1/89 3/91 0.1 0.33 [ 0.03, 3.27 ]
Rasmussen 1986 4/56 14/74 0.4 0.33 [ 0.10, 1.06 ]
Shechter 1990 1/50 9/53 0.3 0.10 [ 0.01, 0.82 ]
Shechter 1991 2/21 4/25 0.1 0.55 [ 0.09, 3.37 ]
Shechter 1995 4/96 17/98 0.6 0.21 [ 0.07, 0.64 ]
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(. . . Continued)
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Smith 1986 2/92 7/93 0.3 0.27 [ 0.06, 1.35 ]
Thogersen 1995 4/130 8/122 0.3 0.45 [ 0.13, 1.54 ]
Urek 1996 1/31 0/30 0.0 3.00 [ 0.12, 76.58 ]
Wu 1992 5/125 12/102 0.5 0.31 [ 0.11, 0.92 ]
Zhu 2002 101/1691 134/1488 4.9 0.64 [ 0.49, 0.84 ]
Subtotal (95% CI) 2596 2385 8.0 0.55 [ 0.44, 0.69 ]
Total events: 139 (Treatment), 222 (Control)
Test for heterogeneity chi-square=14.04 df=12 p=0.30 I² =14.5%
Test for overall effect z=5.26 p<0.00001
Total (95% CI) 36330 36142 100.0 0.99 [ 0.94, 1.04 ]
Total events: 2936 (Treatment), 2958 (Control)
Test for heterogeneity chi-square=57.77 df=22 p=<0.0001 I² =61.9%
Test for overall effect z=0.48 p=0.6
0.1 0.2 0.5 1 2 5 10
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Analysis 01.02. Comparison 01 Magnesium vs placebo on mortality, Outcome 02 mortality by use of
thrombolytic therapy
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 01 Magnesium vs placebo on mortality
Outcome: 02 mortality by use of thrombolytic therapy
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
01 with thrombolytic therapy
ISIS-4 1995 1387/19937 1264/19763 44.2 1.09 [ 1.01, 1.18 ]
MAGIC 2000 175/958 161/961 4.9 1.11 [ 0.88, 1.41 ]
Raghu 1999 6/169 18/181 0.6 0.33 [ 0.13, 0.86 ]
Zhu 2002 50/809 59/668 2.3 0.68 [ 0.46, 1.01 ]
Subtotal (95% CI) 21873 21573 52.0 1.07 [ 0.99, 1.15 ]
Total events: 1618 (Treatment), 1502 (Control)
Test for heterogeneity chi-square=11.36 df=3 p=0.010 I² =73.6%
Test for overall effect z=1.78 p=0.08
02 Without thrombolytic therapy
Abraham 1987 1/48 1/46 0.0 0.96 [ 0.06, 15.77 ]
0.1 0.2 0.5 1 2 5 10
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(. . . Continued)
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Feldstedt 1991 10/150 8/148 0.3 1.25 [ 0.48, 3.26 ]
ISIS-4 1995 794/8570 810/8755 27.2 1.00 [ 0.90, 1.11 ]
MAGIC 2000 300/2152 311/2137 10.0 0.95 [ 0.80, 1.13 ]
Morton 1984 1/40 2/36 0.1 0.44 [ 0.04, 5.02 ]
Rasmussen 1986 4/56 14/74 0.4 0.33 [ 0.10, 1.06 ]
Shechter 1990 1/50 9/53 0.3 0.10 [ 0.01, 0.82 ]
Shechter 1991 2/21 4/25 0.1 0.55 [ 0.09, 3.37 ]
Shechter 1995 4/96 17/98 0.6 0.21 [ 0.07, 0.64 ]
Singh 1990 6/81 11/81 0.4 0.51 [ 0.18, 1.45 ]
Smith 1986 2/92 7/93 0.3 0.27 [ 0.06, 1.35 ]
Zhu 2002 51/874 75/816 2.7 0.61 [ 0.42, 0.89 ]
Subtotal (95% CI) 12230 12362 42.4 0.93 [ 0.86, 1.01 ]
Total events: 1176 (Treatment), 1269 (Control)
Test for heterogeneity chi-square=25.69 df=11 p=0.007 I² =57.2%
Test for overall effect z=1.69 p=0.09
03 mixture of both fibrinolytic and non-fibrinolytic or unclear
Bhargava 1995 3/40 3/38 0.1 0.95 [ 0.18, 5.00 ]
Ceremuzynski 1989 1/25 3/23 0.1 0.28 [ 0.03, 2.88 ]
Gyamlani 2000 2/50 10/50 0.4 0.17 [ 0.03, 0.81 ]
Nakashima 2004 1/89 3/91 0.1 0.33 [ 0.03, 3.27 ]
Santoro 2000 0/75 1/75 0.1 0.33 [ 0.01, 8.20 ]
Thogersen 1995 4/130 8/122 0.3 0.45 [ 0.13, 1.54 ]
Urek 1996 1/31 0/30 0.0 3.00 [ 0.12, 76.58 ]
Woods 1992 90/1150 118/1150 4.1 0.74 [ 0.56, 0.99 ]
Wu 1992 5/125 12/102 0.5 0.31 [ 0.11, 0.92 ]
Subtotal (95% CI) 1715 1681 5.6 0.64 [ 0.50, 0.83 ]
Total events: 107 (Treatment), 158 (Control)
Test for heterogeneity chi-square=7.87 df=8 p=0.45 I² =0.0%
Test for overall effect z=3.39 p=0.0007
Total (95% CI) 35818 35616 100.0 0.99 [ 0.93, 1.04 ]
Total events: 2901 (Treatment), 2929 (Control)
Test for heterogeneity chi-square=60.55 df=24 p=<0.0001 I² =60.4%
Test for overall effect z=0.51 p=0.6
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Analysis 01.03. Comparison 01 Magnesium vs placebo on mortality, Outcome 03 mortality by dose of
magnesium
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 01 Magnesium vs placebo on mortality
Outcome: 03 mortality by dose of magnesium
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Mg dose <75 mmol
Abraham 1987 1/48 1/46 0.0 0.96 [ 0.06, 15.77 ]
Bhargava 1995 3/40 3/38 0.1 0.95 [ 0.18, 5.00 ]
Ceremuzynski 1989 1/25 3/23 0.1 0.28 [ 0.03, 2.88 ]
Gyamlani 2000 2/50 10/50 0.4 0.17 [ 0.03, 0.81 ]
Nakashima 2004 1/89 3/91 0.1 0.33 [ 0.03, 3.27 ]
Rasmussen 1986 4/56 14/74 0.4 0.33 [ 0.10, 1.06 ]
Santoro 2000 0/75 1/75 0.1 0.33 [ 0.01, 8.20 ]
Shechter 1990 1/50 9/53 0.3 0.10 [ 0.01, 0.82 ]
Shechter 1991 2/21 4/25 0.1 0.55 [ 0.09, 3.37 ]
Shechter 1995 4/96 17/98 0.6 0.21 [ 0.07, 0.64 ]
Singh 1990 6/81 11/81 0.4 0.51 [ 0.18, 1.45 ]
Smith 1986 2/92 7/93 0.3 0.27 [ 0.06, 1.35 ]
Thogersen 1995 4/130 8/122 0.3 0.45 [ 0.13, 1.54 ]
Urek 1996 1/31 0/30 0.0 3.00 [ 0.12, 76.58 ]
Woods 1992 90/1150 118/1150 4.0 0.74 [ 0.56, 0.99 ]
Wu 1992 5/125 12/102 0.5 0.31 [ 0.11, 0.92 ]
Zhu 2002 101/1691 134/1488 4.9 0.64 [ 0.49, 0.84 ]
Subtotal (95% CI) 3850 3639 12.6 0.59 [ 0.49, 0.70 ]
Total events: 228 (Treatment), 355 (Control)
Test for heterogeneity chi-square=16.97 df=16 p=0.39 I² =5.7%
Test for overall effect z=6.03 p<0.00001
02 Mg dose >= 75 mmol
Feldstedt 1991 10/150 8/148 0.3 1.25 [ 0.48, 3.26 ]
ISIS-4 1995 2216/29011 2103/29039 71.6 1.06 [ 1.00, 1.13 ]
MAGIC 2000 475/3113 472/3100 14.8 1.00 [ 0.87, 1.15 ]
Morton 1984 1/40 2/36 0.1 0.44 [ 0.04, 5.02 ]
Raghu 1999 6/169 18/181 0.6 0.33 [ 0.13, 0.86 ]
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(. . . Continued)
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Subtotal (95% CI) 32483 32504 87.4 1.04 [ 0.99, 1.11 ]
Total events: 2708 (Treatment), 2603 (Control)
Test for heterogeneity chi-square=6.72 df=4 p=0.15 I² =40.5%
Test for overall effect z=1.52 p=0.1
Total (95% CI) 36333 36143 100.0 0.99 [ 0.94, 1.04 ]
Total events: 2936 (Treatment), 2958 (Control)
Test for heterogeneity chi-square=57.77 df=21 p=<0.0001 I² =63.6%
Test for overall effect z=0.48 p=0.6
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Analysis 02.01. Comparison 02 Magnesium vs placebo on morbidity, Outcome 01 Ventricular fibrillation
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 02 Magnesium vs placebo on morbidity
Outcome: 01 Ventricular fibrillation
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Abraham 1987 0/48 2/46 0.2 0.18 [ 0.01, 3.93 ]
Bhargava 1995 2/40 3/38 0.3 0.61 [ 0.10, 3.89 ]
Ceremuzynski 1989 0/25 1/23 0.1 0.29 [ 0.01, 7.59 ]
Chen 1991 0/32 1/30 0.1 0.30 [ 0.01, 7.72 ]
Feldstedt 1991 2/150 3/148 0.3 0.65 [ 0.11, 3.97 ]
Gyamlani 2000 0/50 2/50 0.2 0.19 [ 0.01, 4.10 ]
ISIS-4 1995 992/29011 1087/29039 92.5 0.91 [ 0.83, 0.99 ]
Morton 1984 2/40 1/36 0.1 1.84 [ 0.16, 21.22 ]
Nakashima 2004 7/89 4/91 0.3 1.86 [ 0.52, 6.58 ]
Wu 1992 1/125 7/102 0.7 0.11 [ 0.01, 0.90 ]
Zhu 2002 34/1691 57/1488 5.2 0.52 [ 0.33, 0.79 ]
Total (95% CI) 31301 31091 100.0 0.88 [ 0.81, 0.96 ]
Total events: 1040 (Treatment), 1168 (Control)
Test for heterogeneity chi-square=15.00 df=10 p=0.13 I² =33.3%
Test for overall effect z=2.90 p=0.004
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Analysis 02.02. Comparison 02 Magnesium vs placebo on morbidity, Outcome 02 Ventricular tachycardia
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 02 Magnesium vs placebo on morbidity
Outcome: 02 Ventricular tachycardia
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Abraham 1987 3/48 7/46 7.9 0.37 [ 0.09, 1.53 ]
Bhargava 1995 13/40 26/38 21.3 0.22 [ 0.09, 0.58 ]
Ceremuzynski 1989 7/25 18/23 16.0 0.11 [ 0.03, 0.40 ]
Chen 1991 0/32 4/30 5.4 0.09 [ 0.00, 1.76 ]
Feldstedt 1991 1/150 0/148 0.6 2.98 [ 0.12, 73.74 ]
Gyamlani 2000 3/50 11/50 12.3 0.23 [ 0.06, 0.87 ]
Rasmussen 1986 7/56 10/74 8.9 0.91 [ 0.32, 2.57 ]
Santoro 2000 18/75 11/75 9.9 1.84 [ 0.80, 4.22 ]
Wu 1992 5/125 14/102 17.6 0.26 [ 0.09, 0.75 ]
Total (95% CI) 601 586 100.0 0.45 [ 0.31, 0.66 ]
Total events: 57 (Treatment), 101 (Control)
Test for heterogeneity chi-square=23.94 df=8 p=0.002 I² =66.6%
Test for overall effect z=4.14 p=0.00003
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Analysis 02.03. Comparison 02 Magnesium vs placebo on morbidity, Outcome 03 II-III heart block
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 02 Magnesium vs placebo on morbidity
Outcome: 03 II-III heart block
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Feldstedt 1991 8/150 0/148 0.0 17.72 [ 1.01, 309.78 ]
ISIS-4 1995 1115/29011 1068/29039 90.8 1.05 [ 0.96, 1.14 ]
MAGIC 2000 63/3113 56/3100 4.9 1.12 [ 0.78, 1.61 ]
Parikka 1999 0/31 1/26 0.1 0.27 [ 0.01, 6.91 ]
Shechter 1990 7/50 12/53 0.9 0.56 [ 0.20, 1.55 ]
Shechter 1991 2/21 5/25 0.4 0.42 [ 0.07, 2.44 ]
Shechter 1995 10/96 15/98 1.2 0.64 [ 0.27, 1.51 ]
Urek 1996 1/31 1/30 0.1 0.97 [ 0.06, 16.19 ]
Woods 1992 25/1159 19/1157 1.6 1.32 [ 0.72, 2.41 ]
Total (95% CI) 33662 33676 100.0 1.05 [ 0.97, 1.14 ]
Total events: 1231 (Treatment), 1177 (Control)
Test for heterogeneity chi-square=8.89 df=8 p=0.35 I² =10.0%
Test for overall effect z=1.16 p=0.2
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Analysis 02.04. Comparison 02 Magnesium vs placebo on morbidity, Outcome 04 Heart failure
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 02 Magnesium vs placebo on morbidity
Outcome: 04 Heart failure
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Feldstedt 1991 7/150 5/148 0.1 1.40 [ 0.43, 4.51 ]
Gyamlani 2000 15/50 25/50 0.4 0.43 [ 0.19, 0.97 ]
ISIS-4 1995 5069/29011 4730/29039 84.5 1.09 [ 1.04, 1.14 ]
MAGIC 2000 597/3113 562/3100 9.9 1.07 [ 0.94, 1.22 ]
Morton 1984 14/40 5/36 0.1 3.34 [ 1.06, 10.51 ]
Nakashima 2004 18/89 28/91 0.5 0.57 [ 0.29, 1.13 ]
Parikka 1999 7/31 6/26 0.1 0.97 [ 0.28, 3.36 ]
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(. . . Continued)
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Rasmussen 1986 1/56 1/74 0.0 1.33 [ 0.08, 21.69 ]
Santoro 2000 6/75 5/75 0.1 1.22 [ 0.35, 4.18 ]
Shechter 1990 13/50 13/53 0.2 1.08 [ 0.44, 2.63 ]
Shechter 1991 6/21 10/25 0.1 0.60 [ 0.17, 2.07 ]
Shechter 1995 18/96 22/98 0.4 0.80 [ 0.40, 1.60 ]
Woods 1992 130/1159 172/1157 3.3 0.72 [ 0.57, 0.92 ]
Wu 1992 19/125 18/102 0.4 0.84 [ 0.41, 1.69 ]
Total (95% CI) 34066 34074 100.0 1.07 [ 1.03, 1.11 ]
Total events: 5920 (Treatment), 5602 (Control)
Test for heterogeneity chi-square=24.56 df=13 p=0.03 I² =47.1%
Test for overall effect z=3.25 p=0.001
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Analysis 02.05. Comparison 02 Magnesium vs placebo on morbidity, Outcome 05 Profound hypotension
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 02 Magnesium vs placebo on morbidity
Outcome: 05 Profound hypotension
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Abraham 1987 1/48 2/46 0.1 0.47 [ 0.04, 5.35 ]
ISIS-4 1995 4781/29011 4300/29039 98.3 1.14 [ 1.09, 1.19 ]
Morton 1984 1/40 0/36 0.0 2.77 [ 0.11, 70.23 ]
Singh 1990 15/66 9/66 0.2 1.86 [ 0.75, 4.62 ]
Woods 1992 56/1159 56/1157 1.5 1.00 [ 0.68, 1.46 ]
Total (95% CI) 30324 30344 100.0 1.13 [ 1.09, 1.19 ]
Total events: 4854 (Treatment), 4367 (Control)
Test for heterogeneity chi-square=2.38 df=4 p=0.67 I² =0.0%
Test for overall effect z=5.56 p<0.00001
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Analysis 02.06. Comparison 02 Magnesium vs placebo on morbidity, Outcome 06 Cardiogenic shock
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 02 Magnesium vs placebo on morbidity
Outcome: 06 Cardiogenic shock
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Abraham 1987 1/48 1/46 0.1 0.96 [ 0.06, 15.77 ]
Bhargava 1995 0/40 1/38 0.1 0.31 [ 0.01, 7.81 ]
Ceremuzynski 1989 1/25 0/23 0.0 2.88 [ 0.11, 74.23 ]
Gyamlani 2000 2/50 5/50 0.4 0.38 [ 0.07, 2.03 ]
ISIS-4 1995 1306/29011 1173/29039 92.2 1.12 [ 1.03, 1.21 ]
Nakashima 2004 10/89 12/91 0.9 0.83 [ 0.34, 2.04 ]
Rasmussen 1986 0/56 7/74 0.5 0.08 [ 0.00, 1.43 ]
Shechter 1990 1/50 6/53 0.5 0.16 [ 0.02, 1.38 ]
Shechter 1991 1/21 4/25 0.3 0.26 [ 0.03, 2.55 ]
Shechter 1995 1/96 11/98 0.9 0.08 [ 0.01, 0.66 ]
Singh 1990 4/66 4/66 0.3 1.00 [ 0.24, 4.18 ]
Zhu 2002 33/1691 44/1488 3.8 0.65 [ 0.41, 1.03 ]
Total (95% CI) 31243 31091 100.0 1.07 [ 0.99, 1.16 ]
Total events: 1360 (Treatment), 1268 (Control)
Test for heterogeneity chi-square=21.80 df=11 p=0.03 I² =49.5%
Test for overall effect z=1.80 p=0.07
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Analysis 02.07. Comparison 02 Magnesium vs placebo on morbidity, Outcome 07 severe arrhythmia needing
treatment
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 02 Magnesium vs placebo on morbidity
Outcome: 07 severe arrhythmia needing treatment
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Chen 1991 7/32 19/30 5.3 0.16 [ 0.05, 0.50 ]
MAGIC 2000 149/3113 147/3100 48.1 1.01 [ 0.80, 1.28 ]
Rasmussen 1986 12/56 14/74 3.3 1.17 [ 0.49, 2.77 ]
Shechter 1990 16/50 24/53 5.4 0.57 [ 0.25, 1.27 ]
Shechter 1991 8/21 14/25 2.7 0.48 [ 0.15, 1.58 ]
Shechter 1995 26/96 39/98 9.7 0.56 [ 0.31, 1.03 ]
Singh 1990 11/66 30/66 8.6 0.24 [ 0.11, 0.54 ]
Smith 1986 5/92 7/93 2.3 0.71 [ 0.22, 2.31 ]
Urek 1996 7/31 11/30 3.0 0.50 [ 0.16, 1.55 ]
Wu 1992 17/125 36/102 11.8 0.29 [ 0.15, 0.55 ]
Total (95% CI) 3682 3671 100.0 0.72 [ 0.60, 0.85 ]
Total events: 258 (Treatment), 341 (Control)
Test for heterogeneity chi-square=32.52 df=9 p=0.0002 I² =72.3%
Test for overall effect z=3.70 p=0.0002
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Analysis 03.01. Comparison 03 Magnesium vs placebo on side effect, Outcome 01 Bradycardia
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 03 Magnesium vs placebo on side effect
Outcome: 01 Bradycardia
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Bhargava 1995 2/40 1/38 0.4 1.95 [ 0.17, 22.40 ]
ISIS-4 1995 211/29011 133/29039 59.7 1.59 [ 1.28, 1.98 ]
Rasmussen 1986 2/56 6/74 2.3 0.42 [ 0.08, 2.16 ]
Woods 1992 125/1159 93/1157 37.6 1.38 [ 1.04, 1.83 ]
Total (95% CI) 30266 30308 100.0 1.49 [ 1.26, 1.77 ]
Total events: 340 (Treatment), 233 (Control)
Test for heterogeneity chi-square=2.97 df=3 p=0.40 I² =0.0%
Test for overall effect z=4.58 p<0.00001
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Analysis 03.02. Comparison 03 Magnesium vs placebo on side effect, Outcome 02 Flushing
Review: Intravenous magnesium for acute myocardial infarction
Comparison: 03 Magnesium vs placebo on side effect
Outcome: 02 Flushing
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
Abraham 1987 16/48 0/46 2.6 47.22 [ 2.73, 815.40 ]
Gyamlani 2000 5/50 0/50 3.4 12.21 [ 0.66, 226.97 ]
ISIS-4 1995 89/29011 12/29039 90.3 7.44 [ 4.07, 13.60 ]
Raghu 1999 152/169 0/181 0.4 3163.29 [ 188.67, 53035.96 ]
Santoro 2000 7/75 0/75 3.4 16.53 [ 0.93, 294.91 ]
Total (95% CI) 29353 29391 100.0 20.78 [ 12.90, 33.46 ]
Total events: 269 (Treatment), 12 (Control)
Test for heterogeneity chi-square=23.81 df=4 p=<0.0001 I² =83.2%
Test for overall effect z=12.48 p<0.00001
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